So	so	RB	O
far	far	RB	O
,	,	,	O
inflammatory	inflammatory	JJ	O
diseases	disease	NNS	O
,	,	,	O
especially	especially	RB	O
the	the	DT	O
chronic	chronic	JJ	O
inflammatory	inflammatory	JJ	O
disorders	disorder	NNS	O
,	,	,	O
have	have	VBP	O
continuously	continuously	RB	O
to	to	TO	O
be	be	VB	O
a	a	DT	O
major	major	JJ	O
global	global	JJ	O
health	health	NN	O
concern	concern	NN	O
due	due	IN	O
to	to	IN	O
the	the	DT	O
lack	lack	NN	O
of	of	IN	O
effective	effective	JJ	O
and	and	CC	O
well	well	RB	O
-	-	HYPH	O
tolerated	tolerate	VBN	O
drugs	drug	NNS	B
.	.	.	O

Currently	currently	RB	O
,	,	,	O
the	the	DT	O
majority	majority	NN	O
of	of	IN	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
therapies	therapy	NNS	O
have	have	VBP	O
been	be	VBN	O
focussed	focusse	VBN	O
on	on	IN	O
two	two	CD	O
distinct	distinct	JJ	O
strategies	strategy	NNS	O
,	,	,	O
the	the	DT	O
first	first	JJ	O
directly	directly	RB	O
interferes	interfere	VBZ	O
with	with	IN	O
the	the	DT	O
biological	biological	JJ	O
function	function	NN	O
of	of	IN	O
the	the	DT	O
pro	pro	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
mediators	mediator	NNS	O
by	by	IN	O
interacting	interact	VBG	O
with	with	IN	O
them	-PRON-	PRP	O
or	or	CC	O
their	-PRON-	PRP$	O
targets	target	NNS	O
,	,	,	O
and	and	CC	O
the	the	DT	O
second	second	JJ	O
blocks	block	VBZ	O
the	the	DT	O
production	production	NN	O
of	of	IN	O
pro	pro	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
mediators	mediator	NNS	B
.	.	.	O

However	however	RB	O
,	,	,	O
given	give	VBN	O
the	the	DT	O
complex	complex	JJ	O
mechanism	mechanism	NN	O
underlying	underlie	VBG	O
some	some	DT	O
inflammatory	inflammatory	JJ	O
diseases	disease	NNS	O
,	,	,	O
which	which	WDT	O
are	be	VBP	O
involved	involve	VBN	O
with	with	IN	O
multiple	multiple	JJ	O
signalling	signal	VBG	O
pathways	pathway	NNS	O
,	,	,	O
the	the	DT	O
legendary	legendary	JJ	O
magic	magic	JJ	O
bullet	bullet	NN	O
,	,	,	O
a	a	DT	O
drug	drug	NN	O
with	with	IN	O
high	high	JJ	O
potency	potency	NN	O
and	and	CC	O
selectivity	selectivity	NN	O
towards	towards	IN	O
a	a	DT	O
specific	specific	JJ	O
biological	biological	JJ	O
target	target	NN	O
,	,	,	O
is	be	VBZ	O
insufficient	insufficient	JJ	O
for	for	IN	O
curing	cure	VBG	O
them	-PRON-	PRP	B
.	.	.	O

Two	two	CD	O
approaches	approach	NNS	O
are	be	VBP	O
capable	capable	JJ	O
of	of	IN	O
achieving	achieve	VBG	O
multi	multi	JJ	O
-	-	JJ	O
dimensional	dimensional	JJ	O
regulation	regulation	NN	O
of	of	IN	O
disease	disease	NN	O
-	-	HYPH	O
related	relate	VBN	O
signalling	signal	VBG	O
pathways	pathway	NNS	O
,	,	,	O
including	include	VBG	O
the	the	DT	O
drug	drug	NN	O
combination	combination	NN	O
and	and	CC	O
polypharmacology	polypharmacology	NN	O
featuring	feature	VBG	O
simultaneous	simultaneous	JJ	O
modulation	modulation	NN	O
of	of	IN	O
multiple	multiple	JJ	O
targets	target	NNS	O
with	with	IN	O
a	a	DT	O
single	single	JJ	O
drug	drug	NN	O
molecule	molecule	NN	B
,	,	,	B
.	.	.	O

Between	between	IN	O
them	-PRON-	PRP	O
,	,	,	O
the	the	DT	O
latter	latter	JJ	O
benefits	benefit	NNS	O
from	from	IN	O
the	the	DT	O
potential	potential	NN	O
to	to	TO	O
obviate	obviate	VB	O
the	the	DT	O
drugâdrug	drugâdrug	NNP	O
interactions	interaction	NNS	O
and	and	CC	O
minimise	minimise	VB	O
the	the	DT	O
combined	combine	VBN	O
off	off	RP	O
-	-	HYPH	O
target	target	NN	O
effects	effect	NNS	B
.	.	.	O

Talmapimod	Talmapimod	NNP	O
1	1	CD	O
,	,	,	O
as	as	IN	O
a	a	DT	O
highly	highly	RB	O
selective	selective	JJ	O
p38Î±	p38Î±	NNP	O
mitogen	mitogen	NN	O
-	-	HYPH	O
activated	activate	VBN	O
protein	protein	NN	O
kinase	kinase	NN	O
p38Î±	p38Î±	NNP	O
MAPK	MAPK	NNP	O
inhibitor	inhibitor	NN	O
developed	develop	VBN	O
by	by	IN	O
Scios	Scios	NNP	O
.	.	.	O

Inc.	Inc.	NNP	O
from	from	IN	O
compound	compound	NN	O
2	2	CD	B
,	,	,	O
has	have	VBZ	O
been	be	VBN	O
advanced	advance	VBN	O
to	to	IN	O
Phase	Phase	NNP	O
-	-	HYPH	O
II	II	NNP	O
clinical	clinical	JJ	O
trials	trial	NNS	O
for	for	IN	O
the	the	DT	O
treatment	treatment	NN	O
of	of	IN	O
rheumatoid	rheumatoid	NNP	O
arthritis	arthritis	NNP	O
,	,	,	O
multiple	multiple	JJ	O
myeloma	myeloma	NN	O
and	and	CC	O
bone	bone	NN	O
marrow	marrow	NN	O
diseases	disease	NNS	B
.	.	.	O

From	from	IN	O
an	an	DT	O
internal	internal	JJ	O
programme	programme	NN	O
to	to	TO	O
prepare	prepare	VB	O
butylphthalide	butylphthalide	JJ	O
derivatives	derivative	NNS	O
,	,	,	O
an	an	DT	O
undesired	undesired	JJ	O
compound	compound	NN	O
6a	6a	CD	O
was	be	VBD	O
obtained	obtain	VBN	O
via	via	IN	O
the	the	DT	O
previously	previously	RB	O
designed	design	VBN	O
synthetic	synthetic	JJ	O
route	route	NN	O
.	.	.	O

Owing	owe	VBG	O
to	to	IN	O
its	-PRON-	PRP$	O
structural	structural	JJ	O
similarity	similarity	NN	O
to	to	IN	O
1	1	CD	O
and	and	CC	O
2	2	CD	O
,	,	,	O
we	-PRON-	PRP	O
are	be	VBP	O
intrigued	intrigue	VBN	O
by	by	IN	O
the	the	DT	O
potential	potential	NN	O
of	of	IN	O
6a	6a	CD	O
and	and	CC	O
its	-PRON-	PRP$	O
derivatives	derivative	NNS	O
as	as	IN	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
agents	agent	NNS	O
.	.	.	O

Hence	hence	RB	O
,	,	,	O
on	on	IN	O
the	the	DT	O
basis	basis	NN	O
of	of	IN	O
6a	6a	NNP	O
,	,	,	O
a	a	DT	O
series	series	NN	O
of	of	IN	O
talmapimod	talmapimod	NNP	O
analogues	analogue	NNS	O
were	be	VBD	O
designed	design	VBN	O
and	and	CC	O
synthesised	synthesise	VBN	O
as	as	IN	O
shown	show	VBN	O
in	in	IN	O
Figure	Figure	NNP	O
2	2	CD	O
.	.	.	O

With	with	IN	O
the	the	DT	O
attempt	attempt	NN	O
to	to	TO	O
validate	validate	VB	O
their	-PRON-	PRP$	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
efficacy	efficacy	NN	O
,	,	,	O
these	these	DT	O
talmapimod	talmapimod	NNP	O
analogues	analogue	NNS	O
were	be	VBD	O
first	first	RB	O
evaluated	evaluate	VBN	O
inÂ	inÂ	NNP	O
vivo	vivo	NN	O
.	.	.	O

The	the	DT	O
most	most	RBS	O
potent	potent	JJ	O
compound	compound	NN	O
6n	6n	CD	O
was	be	VBD	O
further	further	RB	O
tested	test	VBN	O
for	for	IN	O
the	the	DT	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
against	against	IN	O
nitric	nitric	JJ	O
oxide	oxide	NN	O
production	production	NN	O
in	in	IN	O
RAW264.7	RAW264.7	NNP	O
cells	cell	NNS	O
,	,	,	O
and	and	CC	O
its	-PRON-	PRP$	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
mechanism	mechanism	NN	O
was	be	VBD	O
investigated	investigate	VBN	O
by	by	IN	O
western	western	JJ	O
blot	blot	NN	O
.	.	.	O

Additionally	additionally	RB	O
,	,	,	O
according	accord	VBG	O
to	to	IN	O
the	the	DT	O
results	result	NNS	O
of	of	IN	O
mechanism	mechanism	NN	O
study	study	NN	O
,	,	,	O
compounds	compound	VBZ	O
with	with	IN	O
promising	promising	JJ	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
activity	activity	NN	O
inÂ	inÂ	NNP	O
vivo	vivo	NNP	O
were	be	VBD	O
selected	select	VBN	O
for	for	IN	O
evaluating	evaluate	VBG	O
the	the	DT	O
p38Î±	p38Î±	NNP	O
MAPK	MAPK	NNP	O
and	and	CC	O
cyclooxygenases	cyclooxygenase	VBZ	O
inhibitory	inhibitory	NN	O
activities	activity	NNS	O
.	.	.	O

Finally	finally	RB	O
,	,	,	O
molecular	molecular	JJ	O
docking	docking	NN	O
studies	study	NNS	O
were	be	VBD	O
conducted	conduct	VBN	O
to	to	TO	O
elucidate	elucidate	VB	O
the	the	DT	O
possible	possible	JJ	O
binding	bind	VBG	O
modes	mode	NNS	O
with	with	IN	O
these	these	DT	O
proteins	protein	NNS	O
.	.	.	O

Structures	structure	NNS	O
and	and	CC	O
potencies	potency	NNS	O
of	of	IN	O
1	1	CD	O
,	,	,	O
2	2	CD	O
and	and	CC	O
talmapimod	talmapimod	NNP	O
analogue	analogue	NNP	O
6a	6a	CD	O
.	.	.	O

The	the	DT	O
design	design	NN	O
of	of	IN	O
talmapimod	talmapimod	NN	O
analogues	analogue	NNS	O
.	.	.	O

Starting	start	VBG	O
materials	material	NNS	O
,	,	,	O
reagents	reagent	NNS	O
and	and	CC	O
solvents	solvent	NNS	O
were	be	VBD	O
purchased	purchase	VBN	O
from	from	IN	O
common	common	JJ	O
commercial	commercial	JJ	O
suppliers	supplier	NNS	O
.	.	.	O

If	if	IN	O
necessary	necessary	JJ	O
,	,	,	O
purification	purification	NN	O
was	be	VBD	O
carried	carry	VBN	O
out	out	RP	O
prior	prior	RB	O
to	to	IN	O
use	use	VB	O
.	.	.	O

Melting	melt	VBG	O
points	point	NNS	O
were	be	VBD	O
uncorrected	uncorrecte	VBN	O
and	and	CC	O
determined	determine	VBN	O
on	on	IN	O
a	a	DT	O
WRS-1B	WRS-1B	NNP	O
apparatus	apparatus	NN	O
.	.	.	O

1H	1H	NNP	O
and	and	CC	O
13âC	13âC	NNP	O
NMR	NMR	NNP	O
spectra	spectra	NNP	O
were	be	VBD	O
recorded	record	VBN	O
on	on	IN	O
Bruker	Bruker	NNP	O
Avance	Avance	NNP	O
400	400	CD	O
II	ii	CD	O
400âMHz	400âmhz	CD	O
spectrometer	spectrometer	VB	O
using	use	VBG	O
DMSO	DMSO	NNP	O
-	-	HYPH	O
d6	d6	NN	O
with	with	IN	O
tetramethylsilane	tetramethylsilane	NN	O
as	as	IN	O
internal	internal	JJ	O
standard	standard	NN	O
.	.	.	O

ESI	ESI	NNP	O
-	-	HYPH	O
MS	MS	NNP	O
were	be	VBD	O
obtained	obtain	VBN	O
by	by	IN	O
Thermo	Thermo	NNP	O
Q	Q	NNP	O
-	-	HYPH	O
Exactive	Exactive	NNP	O
spectrometer.3	spectrometer.3	JJ	O
-	-	HYPH	O
-3H	-3h	JJ	O
-	-	HYPH	O
isobenzofuran-1-one	isobenzofuran-1-one	NNP	O
.	.	.	O

Iodine	Iodine	NNP	O
9.0âg	9.0âg	CD	O
,	,	,	O
36âmmol	36âmmol	LS	O
was	be	VBD	O
added	add	VBN	O
in	in	IN	O
a	a	DT	O
solution	solution	NN	O
of	of	IN	O
2-vinylbenzoic	2-vinylbenzoic	CD	O
acid	acid	NN	O
2.7âg	2.7âg	CD	O
,	,	,	O
18âmmol	18âmmol	CD	O
in	in	IN	O
CH3CN	CH3CN	NNP	O
30âml	30âml	CD	O
.	.	.	O

The	the	DT	O
reaction	reaction	NN	O
mixture	mixture	NN	O
was	be	VBD	O
stirred	stir	VBN	O
at	at	IN	O
25âÂ	25ââ	CD	O
°	°	,	O
C	C	NNP	O
for	for	IN	O
1âh	1âh	CD	O
under	under	IN	O
N2	N2	NNP	O
atmosphere	atmosphere	NN	O
and	and	CC	O
quenched	quench	VBN	O
with	with	IN	O
saturated	saturated	JJ	O
Na2S2O3	na2s2o3	NN	O
solution	solution	NN	O
.	.	.	O

The	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
extracted	extract	VBN	O
with	with	IN	O
EA	EA	NNP	O
.	.	.	O

The	the	DT	O
EA	EA	NNP	O
layer	layer	NN	O
phase	phase	NN	O
was	be	VBD	O
washed	wash	VBN	O
successively	successively	RB	O
with	with	IN	O
water	water	NN	O
,	,	,	O
NaHCO3	NaHCO3	NNP	O
,	,	,	O
Na2S2O3	na2s2o3	UH	O
,	,	,	O
dried	dry	VBN	O
over	over	IN	O
Na2SO4	Na2SO4	NNP	O
and	and	CC	O
concentrated	concentrate	VBD	O
to	to	IN	O
a	a	DT	O
yellow	yellow	JJ	O
solid	solid	JJ	O
.	.	.	O

The	the	DT	O
crude	crude	JJ	O
product	product	NN	O
was	be	VBD	O
purified	purify	VBN	O
by	by	IN	O
recrystallization	recrystallization	NN	O
from	from	IN	O
hot	hot	JJ	O
ethanol	ethanol	NN	O
,	,	,	O
afforded	afford	VBD	O
the	the	DT	O
title	title	NN	O
compound	compound	NN	O
as	as	IN	O
a	a	DT	O
white	white	JJ	O
crystal	crystal	NN	O
,	,	,	O
Yield	yield	NN	O
:	:	:	O
43	43	CD	O
%	%	NN	O
;	;	:	O
m.p	m.p	NNP	O
.	.	NNP	O

86.9	86.9	CD	O
â	â	NN	O
88.4âÂ	88.4âÂ	NNS	O
°	°	NNS	O
C	c	NN	O
;	;	:	O
1H	1H	NNP	O
NMR	NMR	NNP	O
400âMHz	400âmhz	CD	O
,	,	,	O
DMSO	DMSO	NNP	O
-	-	HYPH	O
d6	d6	NN	O
Î	Î	NNP	O
´	´	CD	O
:	:	:	O
7.92	7.92	CD	O
â	â	NNP	O
7.79	7.79	CD	O
,	,	,	O
7.74	7.74	CD	O
d	d	NN	O
,	,	,	O
1H	1H	NNP	O
Jâ=â7.7	Jâ=â7.7	NNP	O
,	,	,	O
Ar	Ar	NNP	O
-	-	HYPH	O
H	H	NNP	O
,	,	,	O
7.69	7.69	CD	O
â	â	NNP	O
7.61	7.61	CD	O
,	,	,	O
5.66	5.66	CD	O
t	t	NN	O
,	,	,	O
1H	1H	NNP	O
,	,	,	O
Jâ=â4.0âHz	Jâ=â4.0âHz	NNP	O
,	,	,	O
CH	CH	NNP	O
,	,	,	O
3.97	3.97	CD	O
dd	dd	NNP	O
,	,	,	O
1H	1H	NNP	O
,	,	,	O
Jâ=â11.3	Jâ=â11.3	NNP	O
,	,	,	O
3.9âHz	3.9âhz	CD	O
,	,	,	O
CH	CH	NNP	O
,	,	,	O
3.87	3.87	CD	O
dd	dd	NNP	O
,	,	,	O
1H	1H	NNP	O
,	,	,	O
Jâ=â11.3	Jâ=â11.3	NNP	O
,	,	,	O
4.3âHz	4.3âhz	CD	O
,	,	,	O
CH	CH	NNP	O
.	.	.	O

ESI	ESI	NNP	O
-	-	HYPH	O
Mass	Mass	NNP	O
for	for	IN	O
C9H7IO2	C9H7IO2	NNP	O

m	m	NNP	O
/	/	SYM	O
z	z	NNP	O
:	:	:	O
274.7	274.7	CD	O
Mâ+âH]+	mâ+âh]+	NN	O
.	.	.	O

Compound	compound	NN	O
6âb-6s	6âb-6s	CD	O
were	be	VBD	O
prepared	prepare	VBN	O
in	in	IN	O
a	a	DT	O
procedure	procedure	NN	O
similar	similar	JJ	O
to	to	IN	O
that	that	DT	O
described	describe	VBN	O
for	for	IN	O
6a	6a	CD	O
.	.	.	O

Benzoic	Benzoic	NNP	O
acid	acid	NN	O
7	7	CD	O
370âmg	370âmg	CD	O
3âmmol	3âmmol	CD	O
was	be	VBD	O
dissolved	dissolve	VBN	O
in	in	IN	O
DCM	DCM	NNP	O
and	and	CC	O
then	then	RB	O
oxalyl	oxalyl	NNP	O
chloride	chloride	NN	O
630âmg	630âmg	CD	O
,	,	,	O
5âmmol	5âmmol	CD	O
and	and	CC	O
DMF	DMF	NNP	O
were	be	VBD	O
added	add	VBN	O
at	at	IN	O
0âÂ	0ââ	CD	O
°	°	NNP	O
C	C	NNP	O
.	.	.	O

After	after	IN	O
reaction	reaction	NN	O
at	at	IN	O
25âÂ	25ââ	CD	O
°	°	,	O
C	C	NNP	O
for	for	IN	O
2âh	2âh	CD	O
,	,	,	O
the	the	DT	O
reaction	reaction	NN	O
mixture	mixture	NN	O
was	be	VBD	O
concentrated	concentrate	VBN	O
in	in	IN	O
vacuo	vacuo	NNS	O
.	.	.	O

The	the	DT	O
residue	residue	NN	O
in	in	IN	O
DCM	DCM	NNP	O
was	be	VBD	O
added	add	VBN	O
dropwise	dropwise	NN	O
to	to	IN	O
a	a	DT	O
solution	solution	NN	O
of	of	IN	O
1âpiperazine	1âpiperazine	CD	O
840âmg	840âmg	CD	O
,	,	,	O
4.0âmmol	4.0âmmol	CD	O
and	and	CC	O
Et3N	Et3N	NNP	O
610âmg	610âmg	CD	O
,	,	,	O
6âmmol	6âmmol	CD	O
at	at	IN	O
0âÂ	0ââ	CD	O
°	°	NNS	O
C	C	NNP	O
.	.	.	O

The	the	DT	O
reaction	reaction	NN	O
mixture	mixture	NN	O
was	be	VBD	O
stirred	stir	VBN	O
at	at	IN	O
25âÂ	25ââ	CD	O
°	°	,	O
C	C	NNP	O
for	for	IN	O
3âh	3âh	CD	O
and	and	CC	O
concentrated	concentrate	VBD	O
in	in	IN	O
vacuo	vacuo	NNS	O
.	.	.	O

To	to	IN	O
the	the	DT	O
residue	residue	NN	O
was	be	VBD	O
added	add	VBN	O
DCM	DCM	NNP	O
and	and	CC	O
the	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
washed	wash	VBN	O
successively	successively	RB	O
with	with	IN	O
H2O	h2o	NN	O
,	,	,	O
brine	brine	NN	O
,	,	,	O
dried	dry	VBN	O
over	over	IN	O
Na2SO4	Na2SO4	NNP	O
and	and	CC	O
concentrated	concentrate	VBD	O
in	in	IN	O
vacuo	vacuo	NNS	O
.	.	.	O

The	the	DT	O
residue	residue	NN	O
was	be	VBD	O
purified	purify	VBN	O
by	by	IN	O
flash	flash	NN	O
column	column	NN	O
chromatography	chromatography	NN	O
utilising	utilise	VBG	O
PE	PE	NNP	O
/	/	SYM	O
EA	EA	NNP	O
as	as	IN	O
the	the	DT	O
eluent	eluent	NN	O
to	to	TO	O
afford	afford	VB	O
the	the	DT	O
title	title	NN	O
compound	compound	NN	O
as	as	IN	O
white	white	JJ	O
solid	solid	JJ	O
;	;	:	O
Yield	yield	NN	O
:	:	:	O
64	64	CD	O
%	%	NN	O
;	;	:	O
m.p	m.p	NNP	O
.	.	NNP	O

101.0	101.0	CD	O
â	â	NNP	O
101.9âÂ	101.9ââ	NN	O
°	°	,	O
C	C	NNP	O
.	.	.	O

1H	1H	NNP	O
NMR	NMR	NNP	O
400âMHz	400âmhz	CD	O
,	,	,	O
DMSO	DMSO	NNP	O
-	-	HYPH	O
d6	d6	NN	O
Î	Î	NNP	O
´	´	CD	O
:	:	:	O
7.48	7.48	CD	O
â	â	NN	O
7.42	7.42	CD	O
,	,	,	O
7.42	7.42	CD	O
â	â	NN	O
7.36	7.36	CD	O
,	,	,	O
7.36	7.36	CD	O
â	â	NN	O
7.31	7.31	CD	O
,	,	,	O
3.62	3.62	CD	O
,	,	,	O
3.50	3.50	CD	O
,	,	,	O
3.36	3.36	CD	O
,	,	,	O
2.38	2.38	CD	O
d	d	NNP	O
,	,	,	O
Jâ=â26.3âHz	Jâ=â26.3âHz	NNP	O
,	,	,	O
4H	4H	NNP	O
,	,	,	O
piperazine	piperazine	NN	O
-	-	HYPH	O
H	h	NN	O
.	.	.	O

13âC	13âC	NNP	O
NMR	NMR	NNP	O
100âMHz	100âmhz	CD	O
,	,	,	O
DMSO	DMSO	NNP	O
-	-	HYPH	O
d6	d6	NN	O
Î	Î	NNP	O
´	´	CD	O
:	:	:	O
169.34	169.34	CD	O
,	,	,	O
137.27	137.27	CD	O
,	,	,	O
136.32	136.32	CD	O
,	,	,	O
132.04	132.04	CD	O
,	,	,	O
131.14	131.14	CD	O
,	,	,	O
129.95	129.95	CD	O
,	,	,	O
128.86	128.86	CD	O
,	,	,	O
128.65	128.65	CD	O
,	,	,	O
127.35	127.35	CD	O
,	,	,	O
61.31	61.31	CD	O
C-12	c-12	CD	O
,	,	,	O
âCH2	âch2	NN	O
,	,	,	O
53.11	53.11	CD	O
C-9	C-9	NNP	O
,	,	,	O
âCH2	âch2	NN	O
,	,	,	O
Piperazine	Piperazine	NNP	O
,	,	,	O
52.61	52.61	CD	O
C-10	c-10	CD	O
,	,	,	O
âCH2	âch2	NN	O
,	,	,	O
Piperazine	Piperazine	NNP	O
,	,	,	O
47.58	47.58	CD	O
C-11	c-11	CD	O
,	,	,	O
âCH2	âch2	NN	O
,	,	,	O
Piperazine	Piperazine	NNP	O
,	,	,	O
41.96	41.96	CD	O
C-8	C-8	NNP	O
,	,	,	O
âCH2	âCH2	NNP	O
,	,	,	O
Piperazine	Piperazine	NNP	O
.	.	.	O

ESI	ESI	NNP	O
-	-	HYPH	O
Mass	Mass	NNP	O
for	for	IN	O
C18H19ClN2O	C18H19ClN2O	NNP	O
m	m	NNP	O
/	/	SYM	O
z	z	NNP	O
:	:	:	O
315.196	315.196	CD	O
Mâ+âH]+	mâ+âh]+	UH	O
.	.	.	O

Male	Male	NNP	O
ICR	ICR	NNP	O
mice	mouse	NNS	O
20âÂ±â2âg	20ââ±â2âg	CD	O
were	be	VBD	O
obtained	obtain	VBN	O
from	from	IN	O
the	the	DT	O
Experimental	Experimental	NNP	O
Animal	Animal	NNP	O
Centre	Centre	NNP	O
of	of	IN	O
Anhui	Anhui	NNP	O
Medical	Medical	NNP	O
University	University	NNP	O
.	.	.	O

The	the	DT	O
mice	mouse	NNS	O
reared	rear	VBD	O
in	in	IN	O
a	a	DT	O
pathogen	pathogen	NN	O
-	-	HYPH	O
free	free	JJ	O
setting	setting	NN	O
23âÂ±â2âÂ	23ââ±â2ââ	CD	O
°	°	,	O
C	C	NNP	O
,	,	,	O
55âÂ±â5	55ââ±â5	CD	O
%	%	NN	O
humidity	humidity	NN	O
with	with	IN	O
free	free	JJ	O
access	access	NN	O
to	to	IN	O
water	water	NN	O
and	and	CC	O
pelleted	pellete	VBN	O
food	food	NN	O
throughout	throughout	IN	O
the	the	DT	O
experimental	experimental	JJ	O
cycle	cycle	NN	O
.	.	.	O

All	all	DT	O
experimental	experimental	JJ	O
procedures	procedure	NNS	O
performed	perform	VBN	O
in	in	IN	O
accordance	accordance	NN	O
with	with	IN	O
guide	guide	NN	O
for	for	IN	O
the	the	DT	O
Care	Care	NNP	O
and	and	CC	O
Use	Use	NNP	O
of	of	IN	O
Laboratory	Laboratory	NNP	O
Animals	Animals	NNPS	O
and	and	CC	O
were	be	VBD	O
approved	approve	VBN	O
by	by	IN	O
the	the	DT	O
Experimental	Experimental	NNP	O
Animal	Animal	NNP	O
Ethics	Ethics	NNP	O
Committee	Committee	NNP	O
of	of	IN	O
Anhui	Anhui	NNP	O
University	University	NNP	O
of	of	IN	O
Chinese	Chinese	NNP	O
Medicine	Medicine	NNP	O
.	.	.	O

After	after	IN	O
7âdays	7âdays	CD	O
acclimatisation	acclimatisation	NN	O
,	,	,	O
the	the	DT	O
mice	mouse	NNS	O
were	be	VBD	O
randomly	randomly	RB	O
divided	divide	VBN	O
into	into	IN	O
control	control	NN	O
group	group	NN	O
,	,	,	O
ACD	ACD	NNP	O
model	model	NN	O
group	group	NN	O
,	,	,	O
dexamethasone	dexamethasone	NNP	O
positive	positive	JJ	O
control	control	NN	O
group	group	NN	O
and	and	CC	O
20	20	CD	O
compound	compound	NN	O
groups	group	NNS	O
,	,	,	O
six	six	CD	O
in	in	IN	O
each	each	DT	O
group	group	NN	O
.	.	.	O

The	the	DT	O
control	control	NN	O
group	group	NN	O
and	and	CC	O
the	the	DT	O
model	model	NN	O
group	group	NN	O
were	be	VBD	O
given	give	VBN	O
the	the	DT	O
same	same	JJ	O
dose	dose	NN	O
of	of	IN	O
the	the	DT	O
vehicle	vehicle	NN	O
,	,	,	O
the	the	DT	O
positive	positive	JJ	O
control	control	NN	O
group	group	NN	O
was	be	VBD	O
given	give	VBN	O
dexamethasone	dexamethasone	NNP	O
0.5âmg	0.5âmg	NNS	O
/	/	SYM	O
kg	kg	NNS	O
,	,	,	O
and	and	CC	O
the	the	DT	O
test	test	NN	O
compound	compound	NN	O
groups	group	NNS	O
were	be	VBD	O
given	give	VBN	O
compound	compound	NN	O
5âmg	5âmg	NNS	O
/	/	SYM	O
kg	kg	NNS	O
,	,	,	O
all	all	DT	O
of	of	IN	O
which	which	WDT	O
were	be	VBD	O
given	give	VBN	O
by	by	IN	O
intragastric	intragastric	NNP	O
administration	administration	NNP	O
and	and	CC	O
were	be	VBD	O
administered	administer	VBN	O
once	once	RB	O
a	a	DT	O
day	day	NN	O
for	for	IN	O
6âdays	6âdays	CD	O
.	.	.	O

Except	except	IN	O
for	for	IN	O
the	the	DT	O
control	control	NN	O
group	group	NN	O
,	,	,	O
the	the	DT	O
50âÂµL	50ââµl	CD	O
of	of	IN	O
1	1	CD	O
%	%	NN	O
DNFB	DNFB	NNP	O
was	be	VBD	O
administered	administer	VBN	O
to	to	IN	O
the	the	DT	O
stripped	strip	VBN	O
epidermis	epidermis	NN	O
,	,	,	O
and	and	CC	O
repeated	repeat	VBD	O
the	the	DT	O
next	next	JJ	O
day	day	NN	O
.	.	.	O

After	after	IN	O
6âdays	6âdays	CD	O
of	of	IN	O
drug	drug	NN	O
treatment	treatment	NN	O
,	,	,	O
10âÂµL	10ââµl	CD	O
of	of	IN	O
1	1	CD	O
%	%	NN	O
DNFB	DNFB	NNP	O
acetone	acetone	NN	O
olive	olive	NN	O
oil	oil	NN	O
solution	solution	NN	O
was	be	VBD	O
applied	apply	VBN	O
on	on	IN	O
both	both	DT	O
sides	side	NNS	O
of	of	IN	O
the	the	DT	O
right	right	JJ	O
ear	ear	NN	O
to	to	TO	O
stimulate	stimulate	VB	O
inflammation	inflammation	NN	O
,	,	,	O
and	and	CC	O
equivalent	equivalent	JJ	O
acetone	acetone	NN	O
olive	olive	NN	O
oil	oil	NN	O
solution	solution	NN	O
was	be	VBD	O
applied	apply	VBN	O
on	on	IN	O
the	the	DT	O
left	left	JJ	O
ear	ear	NN	O
for	for	IN	O
comparison	comparison	NN	O
.	.	.	O

After	after	IN	O
24âh	24âh	CD	O
,	,	,	O
mice	mouse	NNS	O
were	be	VBD	O
sacrificed	sacrifice	VBN	O
,	,	,	O
ears	ear	NNS	O
were	be	VBD	O
cut	cut	VBN	O
off	off	RP	O
along	along	IN	O
the	the	DT	O
baseline	baseline	NN	O
of	of	IN	O
both	both	DT	O
ears	ear	NNS	O
,	,	,	O
and	and	CC	O
round	round	JJ	O
ear	ear	NN	O
slices	slice	NNS	O
were	be	VBD	O
sheared	shear	VBN	O
in	in	IN	O
the	the	DT	O
same	same	JJ	O
part	part	NN	O
of	of	IN	O
both	both	DT	O
ears	ear	NNS	O
with	with	IN	O
a	a	DT	O
6âmm	6âmm	CD	O
hole	hole	NN	O
puncher	puncher	NN	O
and	and	CC	O
calculate	calculate	VB	O
the	the	DT	O
swelling	swelling	NN	O
degree	degree	NN	O
and	and	CC	O
inhibition	inhibition	NN	O
rate	rate	NN	O
after	after	IN	O
weighing	weigh	VBG	O
.	.	.	O

Calculation	Calculation	NNP	O
was	be	VBD	O
carried	carry	VBN	O
out	out	RP	O
according	accord	VBG	O
to	to	IN	O
the	the	DT	O
following	follow	VBG	O
equations	equation	NNS	O
.	.	.	O

SwellingÂ	swellingâ	JJ	O
degreeÂ	degreeÂ	NNP	O
Â	â	NN	O
=	=	NN	O
Â	Â	NNP	O
MRÂ	MRÂ	NNP	O
âÂ	âÂ	NNP	O
ML	ML	NNP	O
InhibitoryÂ	InhibitoryÂ	NNP	O
rateÂ	rateâ	NN	O
ofÂ	ofâ	JJ	O
earÂ	earâ	CD	O
swellingÂ	swellingÂ	NNP	O
=	=	FW	O
MRÂ	MRÂ	NNP	O
âÂ	âÂ	NNP	O
ML)Â	ML)Â	NNP	O
modelÂ	modelÂ	NNP	O
âÂ	âÂ	NNP	O
MRÂ	MRÂ	NNP	O
âÂ	âÂ	NNP	O
ML)Â	ML)Â	NNP	O
treated)/(MRÂ	treated)/(MRÂ	NNP	O
âÂ	âÂ	NNP	O
ML)Â	ML)Â	NNP	O
modelÂ	modelâ	NN	O
Â	â	NN	O
Â	â	NN	O
Ã100	Ã100	VBZ	O
%	%	NN	O
MR	MR	NNP	O
=	=	SYM	O
AverageÂ	AverageÂ	VBZ	O
weightÂ	weightÂ	NNP	O
ofÂ	ofâ	JJ	O
theÂ	theÂ	VBZ	O
rightÂ	rightÂ	NNP	O
earÂ	earÂ	VBZ	O
slices;ML	slices;ml	ADD	O
=	=	NFP	O
Â	â	NN	O
AverageÂ	AverageÂ	VBZ	O
weightÂ	weightÂ	NNP	O
ofÂ	ofâ	JJ	O
theÂ	theÂ	VBZ	O
leftÂ	leftâ	NN	O
earÂ	earÂ	,	O
slicesMurine	slicesmurine	JJ	O
RAW	raw	JJ	O
264.7	264.7	CD	O
macrophages	macrophage	NNS	O
were	be	VBD	O
obtained	obtain	VBN	O
from	from	IN	O
the	the	DT	O
American	American	NNP	O
Type	Type	NNP	O
Culture	Culture	NNP	O
Collection	Collection	NNP	O
.	.	.	O

The	the	DT	O
cells	cell	NNS	O
were	be	VBD	O
incubated	incubate	VBN	O
in	in	IN	O
DMEM	DMEM	NNP	O
media	medium	NNS	O
supplemented	supplement	VBN	O
with	with	IN	O
10	10	CD	O
%	%	NN	O
FBS	FBS	NNP	O
,	,	,	O
100âU	100âu	CD	O
/	/	SYM	O
mL	mL	NNP	O
penicillin	penicillin	NN	O
and	and	CC	O
100âmg	100âmg	CD	O
/	/	SYM	O
mL	mL	NNP	O
streptomycin	streptomycin	NNP	O
at	at	IN	O
37âÂ	37ââ	CD	O
°	°	,	O
C	C	NNP	O
with	with	IN	O
5	5	CD	O
%	%	NN	O
CO2	CO2	NNP	O
.	.	.	O

Cell	cell	NN	O
viability	viability	NN	O
was	be	VBD	O
assessed	assess	VBN	O
using	use	VBG	O
the	the	DT	O
MTT	MTT	NNP	O
assay	assay	NN	O
.	.	.	O

RAW	raw	JJ	O
264.7	264.7	CD	O
cells	cell	NNS	O
were	be	VBD	O
inoculated	inoculate	VBN	O
in	in	IN	O
96-well	96-well	CD	O
plate	plate	NN	O
at	at	IN	O
a	a	DT	O
density	density	NN	O
of	of	IN	O
1.0âÃâ105	1.0âãâ105	NN	O
cells	cell	NNS	O
per	per	IN	O
well	well	RB	O
.	.	.	O

After	after	IN	O
incubated	incubate	VBD	O
for	for	IN	O
24âh	24âh	CD	O
,	,	,	O
the	the	DT	O
cells	cell	NNS	O
were	be	VBD	O
treated	treat	VBN	O
with	with	IN	O
various	various	JJ	O
concentrations	concentration	NNS	O
of	of	IN	O
the	the	DT	O
compound	compound	NN	O
.	.	.	O

After	after	IN	O
an	an	DT	O
additional	additional	JJ	O
24-h	24-h	CD	O
incubation	incubation	NN	O
,	,	,	O
20âÂµL	20ââµl	CD	O
of	of	IN	O
0.5âmg	0.5âmg	NNS	O
/	/	SYM	O
mL	mL	NNP	O
MTT	MTT	NNP	O
reagent	reagent	NN	O
was	be	VBD	O
added	add	VBN	O
to	to	IN	O
wells	well	NNS	O
and	and	CC	O
incubated	incubate	VBD	O
for	for	IN	O
another	another	DT	O
4âh	4âh	CD	O
.	.	.	O

After	after	IN	O
4âh	4âh	CD	O
,	,	,	O
cell	cell	NN	O
culture	culture	NN	O
media	medium	NNS	O
was	be	VBD	O
removed	remove	VBN	O
and	and	CC	O
DMOS	DMOS	NNP	O
was	be	VBD	O
added	add	VBN	O
into	into	IN	O
each	each	DT	O
well	well	RB	O
,	,	,	O
and	and	CC	O
then	then	RB	O
,	,	,	O
the	the	DT	O
optical	optical	JJ	O
density	density	NN	O
was	be	VBD	O
measured	measure	VBN	O
at	at	IN	O
570ânm	570ânm	CD	O
.	.	.	O

The	the	DT	O
IC50	IC50	NNP	O
values	value	NNS	O
were	be	VBD	O
determined	determine	VBN	O
by	by	IN	O
GraphPad	GraphPad	NNP	O
Prism	Prism	NNP	O
6	6	CD	O
.	.	.	O

The	the	DT	O
RAW	raw	JJ	O
264.7	264.7	CD	O
macrophages	macrophage	NNS	O
were	be	VBD	O
inoculated	inoculate	VBN	O
at	at	IN	O
96-well	96-well	CD	O
plates	plate	NNS	O
and	and	CC	O
were	be	VBD	O
pre	pre	VBN	O
-	-	VBN	O
treated	treat	VBN	O
with	with	IN	O
vehicle	vehicle	NN	O
or	or	CC	O
6n	6n	CD	O
0â20âÂµM	0â20ââµm	CD	O
dose	dose	NNP	O
range	range	NN	O
for	for	IN	O
2âh	2âh	CD	O
and	and	CC	O
then	then	RB	O
stimulated	stimulate	VBD	O
with	with	IN	O
LPS	LPS	NNP	O
200âng	200âng	CD	O
/	/	SYM	O
mL	ml	NN	O
for	for	IN	O
24âh	24âh	CD	O
.	.	.	O

NO	no	DT	O
concentration	concentration	NN	O
in	in	IN	O
the	the	DT	O
medium	medium	NN	O
was	be	VBD	O
determined	determine	VBN	O
using	use	VBG	O
Griess	Griess	NNP	O
reagent	reagent	JJ	O
kit	kit	NN	O
at	at	IN	O
540ânm	540ânm	CD	O
with	with	IN	O
a	a	DT	O
microplate	microplate	NN	O
reader	reader	NN	O
and	and	CC	O
calculated	calculate	VBD	O
the	the	DT	O
inhibition	inhibition	NN	O
rate	rate	NN	O
of	of	IN	O
NO	no	UH	O
.	.	.	O

The	the	DT	O
cell	cell	NN	O
in	in	IN	O
96-well	96-well	CD	O
plates	plate	NNS	O
were	be	VBD	O
treated	treat	VBN	O
as	as	IN	O
described	describe	VBN	O
above	above	RB	O
and	and	CC	O
then	then	RB	O
stimulated	stimulate	VBD	O
with	with	IN	O
LPS	LPS	NNP	O
200âng	200âng	CD	O
/	/	SYM	O
mL	ml	NN	O
for	for	IN	O
24âh	24âh	CD	O
.	.	.	O

The	the	DT	O
cells	cell	NNS	O
were	be	VBD	O
harvested	harvest	VBN	O
and	and	CC	O
lysed	lyse	VBN	O
in	in	IN	O
an	an	DT	O
extraction	extraction	NN	O
lysis	lysis	NN	O
buffer	buffer	NN	O
containing	contain	VBG	O
protease	protease	NN	O
inhibitors	inhibitor	NNS	O
.	.	.	O

The	the	DT	O
protein	protein	NN	O
concentration	concentration	NN	O
was	be	VBD	O
determined	determine	VBN	O
using	use	VBG	O
a	a	DT	O
BCA	BCA	NNP	O
protein	protein	NN	O
assay	assay	NN	O
kit	kit	NN	O
.	.	.	O

The	the	DT	O
whole	whole	JJ	O
cell	cell	NN	O
lysates	lysate	NNS	O
were	be	VBD	O
separated	separate	VBN	O
by	by	IN	O
10	10	CD	O
%	%	NN	O
sodium	sodium	NN	O
dodecyl	dodecyl	VBN	O
sulphate	sulphate	NN	O
-	-	HYPH	O
polyacrylamide	polyacrylamide	NN	O
gel	gel	NN	O
electrophoresis	electrophoresis	NN	O
and	and	CC	O
transferred	transfer	VBN	O
to	to	IN	O
a	a	DT	O
nitrocellulose	nitrocellulose	NN	O
membrane	membrane	NN	O
.	.	.	O

Each	each	DT	O
membrane	membrane	NN	O
was	be	VBD	O
incubated	incubate	VBN	O
with	with	IN	O
Tris	Tris	NNP	O
-	-	HYPH	O
buffered	buffer	VBN	O
saline	saline	NN	O
.	.	.	O

The	the	DT	O
nitrocellulose	nitrocellulose	NN	O
membrane	membrane	NN	O
was	be	VBD	O
incubated	incubate	VBN	O
with	with	IN	O
the	the	DT	O
primary	primary	JJ	O
antibody	antibody	NN	O
against	against	IN	O
p	p	NNP	O
-	-	HYPH	O
JNK1/2	JNK1/2	NNP	O
,	,	,	O
JNK1/2	JNK1/2	NNP	O
,	,	,	O
p	p	NNP	O
-	-	HYPH	O
p38	p38	NNP	O
,	,	,	O
p38	p38	NNP	O
,	,	,	O
p	p	NNP	O
-	-	HYPH	O
ERK1/2	ERK1/2	NNP	O
,	,	,	O
ERK1/2	ERK1/2	NNP	O
,	,	,	O
IÎºBa	IÎºBa	NNP	O
,	,	,	O
NF	NF	NNP	O
-	-	HYPH	O
ÎºB	ÎºB	NNP	O
p65	p65	NN	O
,	,	,	O
COX-2	COX-2	NNP	O
,	,	,	O
iNOS	inos	NN	O
or	or	CC	O
Î²-Actin	î²-actin	ADD	O
.	.	.	O

Immunoreactive	immunoreactive	JJ	O
bands	band	NNS	O
were	be	VBD	O
detected	detect	VBN	O
by	by	IN	O
incubating	incubate	VBG	O
with	with	IN	O
horseradish	horseradish	JJ	O
peroxidase	peroxidase	NN	O
-	-	HYPH	O
conjugated	conjugate	VBN	O
secondary	secondary	JJ	O
antibodies	antibody	NNS	O
,	,	,	O
and	and	CC	O
visualised	visualise	VBD	O
using	use	VBG	O
enhanced	enhanced	JJ	O
chemiluminescence	chemiluminescence	NN	O
reagents	reagent	NNS	O
.	.	.	O

The	the	DT	O
inÂ	inÂ	NNP	O
vitro	vitro	FW	O
ability	ability	NN	O
of	of	IN	O
test	test	NN	O
compounds	compound	NNS	O
and	and	CC	O
SB203580	SB203580	NNP	O
to	to	TO	O
inhibit	inhibit	VB	O
p38Î±	p38Î±	NNP	O
MAPK	MAPK	NNP	O
were	be	VBD	O
measured	measure	VBN	O
according	accord	VBG	O
to	to	IN	O
the	the	DT	O
method	method	NN	O
reported	report	VBN	O
by	by	IN	O
Babu	Babu	NNP	O
J.	J.	NNP	O
Mavunkel	Mavunkel	NNP	B
.	.	.	O

In	in	IN	O
brief	brief	NN	O
,	,	,	O
after	after	IN	O
mixing	mix	VBG	O
the	the	DT	O
enzyme	enzyme	NNS	O
reagent	reagent	VB	O
with	with	IN	O
the	the	DT	O
sample	sample	NN	O
,	,	,	O
a	a	DT	O
reaction	reaction	NN	O
mixture	mixture	NN	O
containing	contain	VBG	O
200âÂµM	200ââµm	CD	O
biotin	biotin	NN	O
-	-	HYPH	O
peptide	peptide	NN	O
substrate	substrate	NN	O
and	and	CC	O
600âÂµM	600ââµm	CD	O
ATP	ATP	NNP	O
+100	+100	NNP	O
ÂµCi	ÂµCi	NNP	O
/	/	SYM	O
mL	mL	NNP	O
Î³-32âP	î³-32âp	XX	O
-	-	HYPH	O
ATP	ATP	NNP	O
was	be	VBD	O
added	add	VBN	O
to	to	TO	O
initiate	initiate	VB	O
the	the	DT	O
reaction	reaction	NN	O
.	.	.	O

After	after	IN	O
incubation	incubation	NN	O
at	at	IN	O
30âÂ	30âÂ	NNP	O
°	°	,	O
C	C	NNP	O
for	for	IN	O
60âmin	60âmin	CD	O
,	,	,	O
10âÂµL	10ââµl	CD	O
of	of	IN	O
1.5	1.5	CD	O
%	%	NN	O
phosphoric	phosphoric	NN	O
acid	acid	NN	O
solution	solution	NN	O
was	be	VBD	O
added	add	VBN	O
to	to	TO	O
terminate	terminate	VB	O
the	the	DT	O
reaction	reaction	NN	O
.	.	.	O

Part	part	NN	O
of	of	IN	O
the	the	DT	O
reaction	reaction	NN	O
solution	solution	NN	O
was	be	VBD	O
transferred	transfer	VBN	O
to	to	IN	O
the	the	DT	O
well	well	NN	O
of	of	IN	O
a	a	DT	O
streptavidin	streptavidin	NNP	O
-	-	HYPH	O
coated	coat	VBN	O
flash	flash	NN	O
plate	plate	NN	O
,	,	,	O
washed	wash	VBN	O
in	in	IN	O
PBS	PBS	NNP	O
containing	contain	VBG	O
0.01	0.01	CD	O
%	%	NN	O
Tween	tween	NN	O
and	and	CC	O
sealed	seal	VBD	O
.	.	.	O

The	the	DT	O
average	average	JJ	O
value	value	NN	O
of	of	IN	O
counts	count	NNS	O
per	per	IN	O
minute	minute	NN	O
for	for	IN	O
each	each	DT	O
group	group	NN	O
and	and	CC	O
the	the	DT	O
IC50	IC50	NNP	O
value	value	NN	O
was	be	VBD	O
calculated	calculate	VBN	O
.	.	.	O

The	the	DT	O
average	average	JJ	O
fluorescence	fluorescence	NN	O
values	value	NNS	O
of	of	IN	O
each	each	DT	O
well	well	RB	O
were	be	VBD	O
calculated	calculate	VBN	O
and	and	CC	O
recorded	record	VBN	O
as	as	IN	O
RFU	RFU	NNP	O
blank	blank	JJ	O
control	control	NN	O
,	,	,	O
RFU	RFU	NNP	O
100	100	CD	O
%	%	NN	O
enzyme	enzyme	NNS	O
activity	activity	NN	O
control	control	NN	O
,	,	,	O
RFU	RFU	NNP	O
positive	positive	JJ	O
drug	drug	NN	O
control	control	NN	O
and	and	CC	O
RFU	rfu	NN	O
test	test	NN	O
compound	compound	NN	O
.	.	.	O

The	the	DT	O
inhibition	inhibition	NN	O
rate	rate	NN	O
is	be	VBZ	O
calculated	calculate	VBN	O
according	accord	VBG	O
to	to	IN	O
the	the	DT	O
following	follow	VBG	O
formula	formula	NN	O
.	.	.	O

InhibitionÂ	inhibitionâ	JJ	O
rateÂ	rateâ	NN	O
=	=	NFP	O
Â	â	NN	O
RFUÂ	RFUÂ	NNS	O
Â	â	NN	O
âÂ	âÂ	NNP	O
RFUÂ	RFUÂ	VBZ	O
Â	â	NN	O
âÂ	âÂ	NNP	O
RFUÂ	rfuâ	NN	O
Â	â	NN	O
Â	â	NN	O
Â	â	NN	O
Â	â	NN	O
Â	â	NN	O
/(RFUÂ	/(RFUÂ	:	O
Â	â	NN	O
âÂ	âÂ	NNP	O
RFUÂ	rfuâ	NN	O
Â	â	NN	O
*	*	NFP	O
Â	â	NN	O
100%The	100%the	CD	O
IC50	IC50	NNP	O
value	value	NN	O
of	of	IN	O
the	the	DT	O
test	test	NN	O
compound	compound	NN	O
was	be	VBD	O
calculated	calculate	VBN	O
by	by	IN	O
the	the	DT	O
concentration	concentration	NN	O
-	-	HYPH	O
inhibition	inhibition	NN	O
reaction	reaction	NN	O
curve	curve	NN	O
and	and	CC	O
the	the	DT	O
assays	assay	NNS	O
were	be	VBD	O
performed	perform	VBN	O
in	in	IN	O
triplicate	triplicate	NN	O
.	.	.	O

The	the	DT	O
COX-1	COX-1	NNP	O
/	/	SYM	O
COX-2	cox-2	JJ	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
of	of	IN	O
test	test	NN	O
compounds	compound	NNS	O
and	and	CC	O
celecoxib	celecoxib	NNP	O
were	be	VBD	O
determined	determine	VBN	O
by	by	IN	O
COX	COX	NNP	O
Inhibitor	Inhibitor	NNP	O
Screening	Screening	NNP	O
Kit	Kit	NNP	O
according	accord	VBG	O
to	to	IN	O
the	the	DT	O
manufacturer	manufacturer	NN	O
's	's	POS	O
instructions	instruction	NNS	O
.	.	.	O

Simply	simply	RB	O
,	,	,	O
different	different	JJ	O
concentrations	concentration	NNS	O
of	of	IN	O
the	the	DT	O
test	test	NN	O
compound	compound	NN	O
solution	solution	NN	O
were	be	VBD	O
added	add	VBN	O
to	to	IN	O
the	the	DT	O
mixed	mix	VBN	O
solution	solution	NN	O
containing	contain	VBG	O
COX-1	COX-1	NNP	O
/	/	SYM	O
COX-2	cox-2	JJ	O
enzyme	enzyme	NNS	O
10âÂµL	10ââµl	CD	O
and	and	CC	O
Assay	Assay	NNP	O
Buffer	Buffer	NNP	O
960âÂµL	960ââµl	CD	O
,	,	,	O
0.1âM	0.1âM	NNP	O
Tris	Tris	NNP	O
-	-	HYPH	O
HCl	HCl	NNP	O
pH	pH	NNP	O
8.0	8.0	CD	O
containing	contain	VBG	O
5âÂµM	5ââµm	CD	O
EDTA	EDTA	NNP	O
and	and	CC	O
2âÂµM	2ââµm	CD	O
phenol	phenol	NNP	O
.	.	.	O

After	after	IN	O
the	the	DT	O
addition	addition	NN	O
of	of	IN	O
the	the	DT	O
arachidonic	arachidonic	JJ	O
acid	acid	NN	O
solution	solution	NN	O
100âÂµM	100ââµm	CD	O
,	,	,	O
the	the	DT	O
mixture	mixture	NN	O
was	be	VBD	O
kept	keep	VBN	O
at	at	IN	O
37âÂ	37ââ	CD	O
°	°	,	O
C	C	NNP	O
in	in	IN	O
the	the	DT	O
dark	dark	NN	O
for	for	IN	O
5âmin	5âmin	CD	O
and	and	CC	O
then	then	RB	O
added	add	VBD	O
50âÂµL	50ââµl	CD	O
of	of	IN	O
1âM	1âm	CD	O
HCl	HCl	NNS	O
to	to	TO	O
stop	stop	VB	O
the	the	DT	O
reaction	reaction	NN	O
.	.	.	O

The	the	DT	O
fluorescence	fluorescence	NN	O
value	value	NN	O
was	be	VBD	O
measured	measure	VBN	O
with	with	IN	O
an	an	DT	O
excitation	excitation	NN	O
wavelength	wavelength	NN	O
of	of	IN	O
535ânm	535ânm	CD	O
and	and	CC	O
an	an	DT	O
emission	emission	NN	O
wavelength	wavelength	NN	O
of	of	IN	O
587ânm	587ânm	CD	O
.	.	.	O

The	the	DT	O
IC50	IC50	NNP	O
values	value	NNS	O
were	be	VBD	O
calculated	calculate	VBN	O
as	as	IN	O
described	describe	VBN	O
above	above	RB	O
.	.	.	O

The	the	DT	O
X	X	NNP	O
-	-	NN	O
ray	ray	NN	O
crystal	crystal	NN	O
structure	structure	NN	O
of	of	IN	O
p38Î±	p38Î±	NNP	O
MAPK	MAPK	NNP	O
,	,	,	O
COX-1	COX-1	NNP	O
and	and	CC	O
COX-2	COX-2	NNP	O
were	be	VBD	O
obtained	obtain	VBN	O
from	from	IN	O
Protein	Protein	NNP	O
Data	Data	NNPS	O
Bank	Bank	NNP	O
.	.	.	O

Before	before	IN	O
docking	docking	NN	O
,	,	,	O
the	the	DT	O
3âD	3âd	JJ	O
structures	structure	NNS	O
of	of	IN	O
6n	6n	CD	O
was	be	VBD	O
generated	generate	VBN	O
and	and	CC	O
the	the	DT	O
energy	energy	NN	O
minimisation	minimisation	NN	O
was	be	VBD	O
carried	carry	VBN	O
out	out	RP	O
;	;	:	O
removing	remove	VBG	O
water	water	NN	O
moleculars	molecular	NNS	O
and	and	CC	O
adding	add	VBG	O
hydrogen	hydrogen	NN	O
atoms	atom	NNS	O
to	to	IN	O
p38Î±	p38Î±	NNP	O
MAPK	MAPK	NNP	O
,	,	,	O
COX-1	COX-1	NNP	O
and	and	CC	O
COX-2	COX-2	NNP	O
with	with	IN	O
the	the	DT	O
AutoDock	AutoDock	NNP	O
Tools	tool	NNS	B
.	.	.	O

Then	then	RB	O
,	,	,	O
the	the	DT	O
docking	docking	NN	O
was	be	VBD	O
performed	perform	VBN	O
by	by	IN	O
Autodock	Autodock	NNP	O
4.2	4.2	CD	O
programme	programme	NN	O
with	with	IN	O
Lamarckian	lamarckian	JJ	O
genetic	genetic	JJ	O
algorithm	algorithm	NN	O
to	to	TO	O
sift	sift	VB	O
the	the	DT	O
best	good	JJS	O
ligand	ligand	NN	O
enzyme	enzyme	VBZ	O
interaction	interaction	NN	O
.	.	.	O

The	the	DT	O
final	final	JJ	O
graphical	graphical	JJ	O
representations	representation	NNS	O
were	be	VBD	O
rendered	render	VBN	O
by	by	IN	O
PyMOL	pymol	JJ	B
.	.	.	O

The	the	DT	O
generation	generation	NN	O
of	of	IN	O
compound	compound	NNP	O
6a	6a	CD	O
,	,	,	O
an	an	DT	O
unexpected	unexpected	JJ	O
product	product	NN	O
,	,	,	O
from	from	IN	O
the	the	DT	O
reaction	reaction	NN	O
between	between	IN	O
3	3	CD	O
and	and	CC	O
4	4	CD	O
.	.	.	O

In	in	IN	O
our	-PRON-	PRP$	O
attempt	attempt	NN	O
to	to	TO	O
prepare	prepare	VB	O
the	the	DT	O
3-butylphthalide	3-butylphthalide	CD	O
derivative	derivative	JJ	O
5	5	CD	O
via	via	IN	O
the	the	DT	O
nucleophilic	nucleophilic	JJ	O
substitution	substitution	NN	O
between	between	IN	O
1âpiperazine	1âpiperazine	CD	O
3	3	CD	O
and	and	CC	O
3-isobenzofuran-1	3-isobenzofuran-1	CD	O
-one	-one	SYM	O
4	4	CD	O
,	,	,	O
an	an	DT	O
unexpected	unexpected	JJ	O
main	main	JJ	O
product	product	NN	O
was	be	VBD	O
afforded	afford	VBN	O
.	.	.	O

Despite	despite	IN	O
its	-PRON-	PRP$	O
MS	MS	NNP	O
consistent	consistent	JJ	O
with	with	IN	O
the	the	DT	O
chemical	chemical	NN	O
structure	structure	NN	O
of	of	IN	O
5	5	CD	O
,	,	,	O
no	no	DT	O
characteristic	characteristic	JJ	O
signal	signal	NN	O
of	of	IN	O
2-CH	2-ch	CD	O
appeared	appear	VBD	O
in	in	IN	O
the	the	DT	O
1H	1h	JJ	O
NMR	NMR	NNP	O
spectrum	spectrum	NN	O
,	,	,	O
while	while	IN	O
a	a	DT	O
singlet	singlet	NN	O
with	with	IN	O
the	the	DT	O
integral	integral	NN	O
of	of	IN	O
3	3	CD	O
existed	exist	VBD	O
at	at	IN	O
2.56âppm	2.56âppm	CD	O
.	.	.	O

Meanwhile	meanwhile	RB	O
,	,	,	O
two	two	CD	O
signals	signal	NNS	O
appeared	appear	VBD	O
at	at	IN	O
170.28	170.28	CD	O
and	and	CC	O
198.57âppm	198.57âppm	CD	O
,	,	,	O
respectively	respectively	RB	O
,	,	,	O
in	in	IN	O
the	the	DT	O
13âC	13âc	JJ	O
NMR	NMR	NNP	O
spectrum	spectrum	NN	O
,	,	,	O
indicating	indicate	VBG	O
the	the	DT	O
existence	existence	NN	O
of	of	IN	O
two	two	CD	O
carbonyl	carbonyl	NN	O
groups	group	NNS	O
in	in	IN	O
the	the	DT	O
chemical	chemical	NN	O
structure	structure	NN	O
of	of	IN	O
the	the	DT	O
product	product	NN	O
.	.	.	O

Taken	take	VBN	O
together	together	RB	O
,	,	,	O
it	-PRON-	PRP	O
was	be	VBD	O
speculated	speculate	VBN	O
that	that	IN	O
the	the	DT	O
afforded	afford	VBN	O
product	product	NN	O
was	be	VBD	O
6a	6a	CD	O
.	.	.	O

The	the	DT	O
singlet	singlet	NN	O
at	at	IN	O
2.56âppm	2.56âppm	CD	O
was	be	VBD	O
generated	generate	VBN	O
from	from	IN	O
its	-PRON-	PRP$	O
acetyl	acetyl	NN	O
moiety	moiety	NN	O
.	.	.	O

The	the	DT	O
possible	possible	JJ	O
mechanism	mechanism	NN	O
for	for	IN	O
the	the	DT	O
generation	generation	NN	O
of	of	IN	O
6a	6a	NNP	O
.	.	.	O

The	the	DT	O
speculated	speculated	JJ	O
mechanism	mechanism	NN	O
for	for	IN	O
the	the	DT	O
generation	generation	NN	O
of	of	IN	O
6a	6a	NNP	O
was	be	VBD	O
displayed	display	VBN	O
in	in	IN	O
Figure	Figure	NNP	O
4	4	CD	O
.	.	.	O

Intermediate	intermediate	NN	O
4	4	CD	O
firstly	firstly	RB	O
underwent	underwent	JJ	O
elimination	elimination	NN	O
to	to	TO	O
give	give	VB	O
enol	enol	NNP	O
ester	ester	NN	O
4a	4a	CD	O
.	.	.	O

Afterwards	afterwards	RB	O
,	,	,	O
the	the	DT	O
five	five	CD	O
-	-	HYPH	O
membered	membere	VBN	O
lactone	lactone	NN	O
was	be	VBD	O
opened	open	VBN	O
in	in	IN	O
the	the	DT	O
presence	presence	NN	O
of	of	IN	O
1âpiperazine	1âpiperazine	CD	O
.	.	.	O

Finally	finally	RB	O
,	,	,	O
the	the	DT	O
proton	proton	NNP	O
on	on	IN	O
the	the	DT	O
piperazine	piperazine	NN	O
was	be	VBD	O
transferred	transfer	VBN	O
to	to	IN	O
the	the	DT	O
carbonyl	carbonyl	NN	O
alpha	alpha	NN	O
site	site	NN	O
to	to	TO	O
form	form	VB	O
compound	compound	NNP	O
6a	6a	NNP	O
.	.	.	O

Compound	Compound	NNP	O
6n	6n	CD	O
inhibited	inhibit	VBD	O
LPS	LPS	NNP	O
-	-	HYPH	O
induced	induce	VBN	O
NF	NF	NNP	O
-	-	HYPH	O
ÎºB	ÎºB	NNP	O
activation	activation	NN	O
in	in	IN	O
RAW264.7	RAW264.7	NNP	O
cells	cell	NNS	O
.	.	.	O

RAW264.7	RAW264.7	NNP	O
cells	cell	NNS	O
were	be	VBD	O
co	co	VBN	O
-	-	VBN	O
incubated	incubate	VBN	O
with	with	IN	O
6n	6n	NNP	O
5	5	CD	O
,	,	,	O
10	10	CD	O
,	,	,	O
20âÎ¼M	20âî¼m	CD	O
and	and	CC	O
LPS	LPS	NNP	O
200âng	200âng	CD	O
/	/	SYM	O
mL	ml	NN	O
for	for	IN	O
30âmin	30âmin	NNP	O
.	.	.	O

The	the	DT	O
levels	level	NNS	O
of	of	IN	O
NF	NF	NNP	O
-	-	HYPH	O
ÎºB	ÎºB	NNP	O
p65	p65	NN	O
,	,	,	O
IÎºB	IÎºB	NNP	O
,	,	,	O
and	and	CC	O
their	-PRON-	PRP$	O
phosphorylated	phosphorylated	JJ	O
forms	form	NNS	O
were	be	VBD	O
analysed	analyse	VBN	O
using	use	VBG	O
western	western	JJ	O
blot	blot	NN	O
.	.	.	O

The	the	DT	O
results	result	NNS	O
were	be	VBD	O
showed	show	VBN	O
as	as	IN	O
meansâÂ±âSD	meansâÂ±âSD	NNP	O
nâ=â3	nâ=â3	NNP	O
;	;	:	O
*	*	NFP	O
*	*	NFP	O
pâ<â0.01	pâ<â0.01	-LRB-	O
vs.	vs.	FW	O
compared	compare	VBN	O
with	with	IN	O
the	the	DT	O
control	control	NN	O
group	group	NN	O
;	;	:	O
#	#	$	O
pâ<â0.05	pâ<â0.05	NNP	O
,	,	,	O
#	#	$	O
#	#	$	O
pâ<â0.01	pâ<â0.01	PRP$	O
vs.	vs.	FW	O
compare	compare	VBP	O
with	with	IN	O
LPS	LPS	NNP	O
-	-	HYPH	O
stimulated	stimulate	VBN	O
group	group	NN	O
.	.	.	O

The	the	DT	O
synthetic	synthetic	JJ	O
route	route	NN	O
to	to	TO	O
target	target	VB	O
talmapimod	talmapimod	NNP	O
analogues	analogue	VBZ	O
6a	6a	NNP	O
-	-	HYPH	O
s	s	NNPS	O
and	and	CC	O
8	8	CD	O
was	be	VBD	O
displayed	display	VBN	O
in	in	IN	O
Scheme	Scheme	NNP	O
1	1	CD	O
.	.	.	O

3-isobenzofuran-1	3-isobenzofuran-1	CD	O
-one	-one	IN	O
4	4	CD	O
was	be	VBD	O
prepared	prepare	VBN	O
according	accord	VBG	O
to	to	IN	O
the	the	DT	O
procedure	procedure	NN	O
reported	report	VBN	O
by	by	IN	O
Siegfried	Siegfried	NNP	O
H.	H.	NNP	O
Reich	Reich	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	.	B
.	.	.	O

It	-PRON-	PRP	O
was	be	VBD	O
treated	treat	VBN	O
with	with	IN	O
a	a	DT	O
series	series	NN	O
of	of	IN	O
benzyl	benzyl	NNP	O
piperazine	piperazine	NN	O
derivatives	derivative	NNS	O
in	in	IN	O
the	the	DT	O
presence	presence	NN	O
of	of	IN	O
K2CO3	K2CO3	NNP	O
to	to	TO	O
furnish	furnish	VB	O
compounds	compound	NNS	O
6a	6a	NNP	O
-	-	HYPH	O
s	s	NN	O
.	.	.	O

After	after	IN	O
converting	convert	VBG	O
benzoic	benzoic	JJ	O
acid	acid	NN	O
7	7	CD	O
into	into	IN	O
benzoyl	benzoyl	JJ	O
chloride	chloride	NN	O
,	,	,	O
it	-PRON-	PRP	O
was	be	VBD	O
condensed	condense	VBN	O
with	with	IN	O
1âpiperazine	1âpiperazine	CD	O
3	3	CD	O
to	to	TO	O
afford	afford	VB	O
8	8	CD	O
as	as	IN	O
the	the	DT	O
product	product	NN	O
.	.	.	O

Reagents	reagent	NNS	O
and	and	CC	O
conditions	condition	NNS	O
:	:	:	O
I2	I2	NNP	O
,	,	,	O
CH3CN	CH3CN	NNP	O
,	,	,	O
25âÂ	25ââ	CD	O
°	°	,	O
C	C	NNP	O
;	;	:	O
K2CO3	K2CO3	NNP	O
,	,	,	O
CH3CN	CH3CN	NNP	O
,	,	,	O
25âÂ	25ââ	CD	O
°	°	,	O
C	C	NNP	O
;	;	:	O
oxalyl	oxalyl	NNP	O
chloride	chloride	NN	O
,	,	,	O
1âpiperazine	1âpiperazine	NNP	O
,	,	,	O
DCM	DCM	NNP	O
,	,	,	O
Et3N	Et3N	NNP	O
,	,	,	O
25âÂ	25ââ	CD	O
°	°	,	O
C	C	NNP	O
.	.	.	O

To	to	TO	O
validate	validate	VB	O
their	-PRON-	PRP$	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
efficacy	efficacy	NN	O
,	,	,	O
we	-PRON-	PRP	O
evaluated	evaluate	VBD	O
compounds	compound	VBZ	O
6a	6a	NNPS	O
-	-	HYPH	O
s	s	NNPS	O
and	and	CC	O
8	8	CD	O

inÂ	inâ	JJ	O
vivo	vivo	NN	O
at	at	IN	O
a	a	DT	O
p.o	p.o	NNP	O
.	.	NNP	O

dose	dose	NN	O
of	of	IN	O
5âmg	5âmg	NNP	O
/	/	SYM	O
kg	kg	NNS	O
in	in	IN	O
a	a	DT	O
2,4-dinitrofluorobenzenethe	2,4-dinitrofluorobenzenethe	CD	O
-	-	HYPH	O
induced	induce	VBN	O
mouse	mouse	NN	O
model	model	NN	O
of	of	IN	O
allergic	allergic	JJ	O
contact	contact	NN	O
dermatitis	dermatitis	NN	B
.	.	.	O

Dexamethasone	dexamethasone	NN	O
at	at	IN	O
a	a	DT	O
p.o	p.o	NNP	O
.	.	NNP	O

dose	dose	NN	O
of	of	IN	O
0.5âmg	0.5âmg	NNP	O
/	/	SYM	O
kg	kg	NNP	O
was	be	VBD	O
employed	employ	VBN	O
as	as	IN	O
the	the	DT	O
positive	positive	JJ	O
control	control	NN	O
.	.	.	O

After	after	IN	O
the	the	DT	O
mice	mouse	NNS	O
were	be	VBD	O
sacrificed	sacrifice	VBN	O
,	,	,	O
the	the	DT	O
swelling	swelling	NN	O
degree	degree	NN	O
and	and	CC	O
inhibition	inhibition	NN	O
rate	rate	NN	O
were	be	VBD	O
calculated	calculate	VBN	O
by	by	IN	O
weighing	weigh	VBG	O
the	the	DT	O
same	same	JJ	O
part	part	NN	O
of	of	IN	O
both	both	DT	O
ears	ear	NNS	O
.	.	.	O

The	the	DT	O
results	result	NNS	O
demonstrated	demonstrate	VBD	O
that	that	IN	O
compounds	compound	VBZ	O
6f	6f	RB	O
,	,	,	O
6j	6j	NNS	O
,	,	,	O
6n	6n	CD	O
,	,	,	O
6p	6p	NN	O
and	and	CC	O
8	8	CD	O
had	have	VBD	O
significant	significant	JJ	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
pâ<â0.01	pâ<â0.01	ADD	O
.	.	.	O

In	in	IN	O
particular	particular	JJ	O
,	,	,	O
6n	6n	CD	O
exerted	exert	VBD	O
the	the	DT	O
strongest	strong	JJS	O
inÂ	inâ	JJ	O
vivo	vivo	NNP	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
activity	activity	NN	O
with	with	IN	O
the	the	DT	O
inhibition	inhibition	NN	O
rate	rate	NN	O
of	of	IN	O
46.3	46.3	CD	O
%	%	NN	O
.	.	.	O

Hence	hence	RB	O
,	,	,	O
6n	6n	CD	O
was	be	VBD	O
further	further	RB	O
selected	select	VBN	O
for	for	IN	O
exploring	explore	VBG	O
the	the	DT	O
molecular	molecular	JJ	O
mechanisms	mechanism	NNS	O
underlying	underlie	VBG	O
its	-PRON-	PRP$	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
efficacy	efficacy	NN	O
.	.	.	O

Results	result	NNS	O
of	of	IN	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
activity	activity	NN	O
inÂ	inÂ	NNP	O
vivo	vivo	NN	O
of	of	IN	O
compounds	compound	NNS	O
and	and	CC	O
DEX	DEX	NNP	O
MeanâÂ±âSD	meanââ±âsd	CD	O
,	,	,	O
nâ=â6	nâ=â6	NNP	O
.	.	.	O

â³pâ<â0.05	â³pâ<â0.05	NNP	O
,	,	,	O
â³â³pâ<â0.01	â³â³pâ<â0.01	CC	O
vs	vs	IN	O
control	control	NNP	O
;	;	:	O
â²pâ<â0.05	â²pâ<â0.05	CD	O
,	,	,	O
â²â²pâ<â0.01	â²â²pâ<â0.01	ADD	O
vs	vs	IN	O
model.swelling	model.swelle	VBG	O
degree	degree	NN	O
=	=	SYM	O
MRâââML.inhibition	MRâââML.inhibition	''	O
=	=	FW	O
MRâââML	MRâââML	NNP	O
modelâ(MRâââML	modelâ(MRâââML	NNP	O
treated)/(MRâââML	treated)/(MRâââML	NNP	O
model	model	NN	O
*	*	NFP	O
100	100	CD	O
%	%	NN	O
.	.	.	O

MR	MR	NNP	O
:	:	:	O
Average	average	JJ	O
weight	weight	NN	O
of	of	IN	O
the	the	DT	O
right	right	JJ	O
ear	ear	NN	O
;	;	:	O
ML	ML	NNP	O
:	:	:	O
Average	average	JJ	O
weight	weight	NN	O
of	of	IN	O
the	the	DT	O
left	left	JJ	O
ear	ear	NN	O
.	.	.	O

NO	no	RB	O
serves	serve	VBZ	O
as	as	IN	O
an	an	DT	O
important	important	JJ	O
inflammation	inflammation	NN	O
mediator	mediator	NN	O
,	,	,	O
and	and	CC	O
its	-PRON-	PRP$	O
continuous	continuous	JJ	O
high	high	JJ	O
concentration	concentration	NN	O
is	be	VBZ	O
involved	involve	VBN	O
with	with	IN	O
the	the	DT	O
development	development	NN	O
of	of	IN	O
inflammation	inflammation	NN	O
-	-	HYPH	O
related	relate	VBN	O
diseases	disease	NNS	B
.	.	.	O

Besides	besides	RB	O
,	,	,	O
NO	no	DT	O
regulates	regulate	NNS	O
inducible	inducible	JJ	O
nitric	nitric	JJ	O
oxide	oxide	NN	O
synthetase	synthetase	NN	O
and	and	CC	O
cyclooxygenase	cyclooxygenase	VB	O
2	2	CD	B
.	.	.	O

In	in	IN	O
view	view	NN	O
of	of	IN	O
these	these	DT	O
,	,	,	O
we	-PRON-	PRP	O
examined	examine	VBD	O
the	the	DT	O
inhibitory	inhibitory	JJ	O
effect	effect	NN	O
of	of	IN	O
6n	6n	NNP	O
on	on	IN	O
LPS	LPS	NNP	O
-	-	HYPH	O
induced	induce	VBN	O
NO	no	DT	O
production	production	NN	O
and	and	CC	O
LPS	LPS	NNP	O
-	-	HYPH	O
induced	induce	VBN	O
expressions	expression	NNS	O
of	of	IN	O
iNOS	inos	NN	O
and	and	CC	O
COX-2	COX-2	NNP	O
in	in	IN	O
RAW264.7	RAW264.7	NNP	O
cells	cell	NNS	O
.	.	.	O

The	the	DT	O
cytotoxicity	cytotoxicity	NN	O
of	of	IN	O
6n	6n	CD	O
was	be	VBD	O
firstly	firstly	RB	O
evaluated	evaluate	VBN	O
,	,	,	O
and	and	CC	O
no	no	DT	O
significant	significant	JJ	O
toxicity	toxicity	NN	O
was	be	VBD	O
observed	observe	VBN	O
at	at	IN	O
concentrations	concentration	NNS	O
ranging	range	VBG	O
from	from	IN	O
5	5	CD	O
to	to	IN	O
50âÂµM	50ââµm	CD	O
Figures	Figures	NNP	O
5	5	CD	O
and	and	CC	O
6	6	CD	O
.	.	.	O

While	while	IN	O
the	the	DT	O
LPS	LPS	NNP	O
200âng	200âng	CD	O
/	/	SYM	O
mL	ml	NN	O
stimulation	stimulation	NN	O
for	for	IN	O
24âh	24âh	CD	O
significantly	significantly	RB	O
increased	increase	VBN	O
NO	no	DT	O
production	production	NN	O
,	,	,	O
compound	compound	NN	O
6n	6n	CD	O
reduced	reduce	VBN	O
LPS	LPS	NNP	O
-	-	HYPH	O
induced	induce	VBN	O
NO	no	DT	O
production	production	NN	O
in	in	IN	O
a	a	DT	O
dose	dose	RB	O
-	-	HYPH	O
dependent	dependent	JJ	O
manner	manner	NN	O
Figure	Figure	NNP	O
6	6	CD	O
.	.	.	O

Besides	besides	RB	O
,	,	,	O
6n	6n	CD	O
-	-	HYPH	O
treatment	treatment	NN	O
culminated	culminate	VBN	O
in	in	IN	O
a	a	DT	O
dose	dose	RB	O
-	-	HYPH	O
dependent	dependent	JJ	O
decrease	decrease	NN	O
in	in	IN	O
the	the	DT	O
LPS	LPS	NNP	O
-	-	HYPH	O
induced	induce	VBN	O
expressions	expression	NNS	O
of	of	IN	O
iNOS	inos	NN	O
Figure	Figure	NNP	O
6	6	CD	O
and	and	CC	O
COX-2	COX-2	NNP	O
Figure	Figure	NNP	O
6	6	CD	O
.	.	.	O

Compound	compound	NN	O
6n	6n	CD	O
inhibited	inhibit	VBD	O
LPS	LPS	NNP	O
-	-	HYPH	O
induced	induce	VBN	O
iNOS	inos	NN	O
and	and	CC	O
COX-2	cox-2	JJ	O
expressions	expression	NNS	O
in	in	IN	O
RAW264.7	RAW264.7	NNP	O
cells	cell	NNS	O
.	.	.	O

The	the	DT	O
cells	cell	NNS	O
were	be	VBD	O
pre	pre	VBN	O
-	-	VBN	O
treated	treat	VBN	O
with	with	IN	O
different	different	JJ	O
concentrations	concentration	NNS	O
of	of	IN	O
6n	6n	CD	O
and	and	CC	O
then	then	RB	O
were	be	VBD	O
stimulated	stimulate	VBN	O
with	with	IN	O
LPS	LPS	NNP	O
200âng	200âng	CD	O
/	/	SYM	O
mL	ml	NN	O
for	for	IN	O
24âh	24âh	CD	O
.	.	.	O

Bay	Bay	NNP	O
11â7082	11â7082	CD	O
is	be	VBZ	O
the	the	DT	O
NF	NF	NNP	O
-	-	HYPH	O
ÎºB	îºb	NN	O
inhibitor	inhibitor	NN	O
.	.	.	O

Cell	cell	NN	O
viability	viability	NN	O
was	be	VBD	O
evaluated	evaluate	VBN	O
using	use	VBG	O
the	the	DT	O
MTT	MTT	NNP	O
assay	assay	NN	O
.	.	.	O

NO	no	DT	O
production	production	NN	O
was	be	VBD	O
measured	measure	VBN	O
using	use	VBG	O
nitrite	nitrite	JJ	O
and	and	CC	O
nitrate	nitrate	JJ	O
assay	assay	NNP	O
.	.	.	O

iNOS	iNOS	NNP	O
and	and	CC	O
COX-2	cox-2	JJ	O
expression	expression	NN	O
were	be	VBD	O
detected	detect	VBN	O
by	by	IN	O
Western	western	JJ	O
blot	blot	NN	O
.	.	.	O

Cell	cell	NN	O
viability	viability	NN	O
assay	assay	NN	O
;	;	:	O
Quantitative	quantitative	JJ	O
analysis	analysis	NN	O
of	of	IN	O
NO	no	DT	O
productions	production	NNS	O
;	;	:	O
Quantitative	quantitative	JJ	O
analysis	analysis	NN	O
of	of	IN	O
iNOS	inos	NN	O
expressions	expression	NNS	O
,	,	,	O
Quantitative	quantitative	JJ	O
analysis	analysis	NN	O
of	of	IN	O
COX-2	cox-2	JJ	O
expressions	expression	NNS	O
.	.	.	O

Î²-actin	Î²-actin	NNP	O
was	be	VBD	O
used	use	VBN	O
as	as	IN	O
loading	loading	NN	O
control	control	NN	O
.	.	.	O

The	the	DT	O
results	result	NNS	O
were	be	VBD	O
showed	show	VBN	O
as	as	IN	O
meansâÂ±âSD	meansâÂ±âSD	NNP	O
nâ=â3	nâ=â3	NNP	O
;	;	:	O
*	*	NFP	O
*	*	NFP	O
pâ<â0.01	pâ<â0.01	VBP	O
vs	vs	IN	O
compared	compare	VBN	O
with	with	IN	O
the	the	DT	O
control	control	NN	O
group	group	NN	O
;	;	:	O
#	#	$	O
pâ<â0.05	pâ<â0.05	NNP	O
,	,	,	O
#	#	$	O
#	#	NN	O
pâ<â0.01	pâ<â0.01	VBP	O
vs	vs	IN	O
compared	compare	VBN	O
with	with	IN	O
LPS	LPS	NNP	O
-	-	HYPH	O
stimulated	stimulate	VBN	O
group	group	NN	O
.	.	.	O

The	the	DT	O
activation	activation	NN	O
of	of	IN	O
NF	NF	NNP	O
-	-	HYPH	O
ÎºB	ÎºB	NNP	O
through	through	IN	O
proteasomal	proteasomal	JJ	O
degradation	degradation	NN	O
and	and	CC	O
phosphorylation	phosphorylation	NN	O
of	of	IN	O
inhibitory	inhibitory	NNP	O
ÎºB	ÎºB	NNP	O
led	lead	VBN	O
to	to	IN	O
the	the	DT	O
translocation	translocation	NN	O
of	of	IN	O
NF	NF	NNP	O
-	-	HYPH	O
ÎºB	ÎºB	NNP	O
p65	p65	NN	O
and	and	CC	O
its	-PRON-	PRP$	O
interaction	interaction	NN	O
with	with	IN	O
the	the	DT	O
gene	gene	NN	O
promoter	promoter	NN	O
region	region	NN	O
in	in	IN	O
nucleus	nucleus	NNP	O
,	,	,	O
thereby	thereby	RB	O
promoting	promote	VBG	O
the	the	DT	O
expression	expression	NN	O
of	of	IN	O
iNOS	inos	NN	O
and	and	CC	O
COX-2	COX-2	NNP	B
,	,	,	B
.	.	.	O

Thus	thus	RB	O
,	,	,	O
western	western	JJ	O
blot	blot	NN	O
was	be	VBD	O
performed	perform	VBN	O
to	to	TO	O
examine	examine	VB	O
the	the	DT	O
effect	effect	NN	O
of	of	IN	O
6n	6n	NNP	O
on	on	IN	O
LPS	LPS	NNP	O
-	-	HYPH	O
induced	induce	VBN	O
transcriptional	transcriptional	JJ	O
activity	activity	NN	O
of	of	IN	O
NF	NF	NNP	O
-	-	HYPH	O
ÎºB	ÎºB	NNP	O
in	in	IN	O
RAW264.7	RAW264.7	NNP	O
cells	cell	NNS	O
.	.	.	O

As	as	IN	O
shown	show	VBN	O
in	in	IN	O
Figure	Figure	NNP	O
5	5	CD	O
,	,	,	O
2-h	2-h	CD	O
pre	pre	JJ	O
-	-	NN	O
treatment	treatment	NN	O
with	with	IN	O
6n	6n	NNP	O
or	or	CC	O
Bay	Bay	NNP	O
11e7082	11e7082	CD	O
before	before	IN	O
LPS	LPS	NNP	O
stimulation	stimulation	NN	O
markedly	markedly	RB	O
decreased	decrease	VBD	O
LPS	LPS	NNP	O
-	-	HYPH	O
induced	induce	VBN	O
IÎºB	IÎºB	NNP	O
phosphorylation	phosphorylation	NN	O
Figure	Figure	NNP	O
5	5	CD	O
and	and	CC	O
increased	increase	VBN	O
cytosolic	cytosolic	JJ	O
IÎºB	IÎºB	NNP	O
Figure	Figure	NNP	O
5	5	CD	O
.	.	.	O

Meanwhile	meanwhile	RB	O
,	,	,	O
the	the	DT	O
accumulation	accumulation	NN	O
of	of	IN	O
NF	NF	NNP	O
-	-	HYPH	O
ÎºB	ÎºB	NNP	O
p65	p65	NN	O
subunit	subunit	NN	O
in	in	IN	O
the	the	DT	O
nucleus	nucleus	NN	O
was	be	VBD	O
also	also	RB	O
lowered	lower	VBN	O
Figure	Figure	NNP	O
5	5	CD	O
.	.	.	O

These	these	DT	O
results	result	NNS	O
indicated	indicate	VBD	O
that	that	IN	O
6n	6n	CD	O
exerted	exert	VBD	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
effects	effect	NNS	O
through	through	IN	O
modulation	modulation	NN	O
of	of	IN	O
NF	NF	NNP	O
-	-	HYPH	O
ÎºB	ÎºB	NNP	O
-	-	HYPH	O
signalling	signal	VBG	O
pathway	pathway	NN	O
.	.	.	O

MAPKs	mapk	NNS	O
play	play	VBP	O
pivotal	pivotal	JJ	O
roles	role	NNS	O
in	in	IN	O
incurring	incur	VBG	O
the	the	DT	O
immune	immune	RB	O
-	-	HYPH	O
mediated	mediate	VBN	O
inflammation	inflammation	NN	O
by	by	IN	O
regulating	regulate	VBG	O
the	the	DT	O
transcription	transcription	NN	O
and	and	CC	O
translation	translation	NN	O
of	of	IN	O
a	a	DT	O
variety	variety	NN	O
of	of	IN	O
crucial	crucial	JJ	O
transcription	transcription	NN	O
factors	factor	NNS	O
,	,	,	O
including	include	VBG	O
activation	activation	NN	O
protein-1	protein-1	NNP	O
and	and	CC	O
NF	NF	NNP	O
-	-	HYPH	O
ÎºB	îºb	NN	B
.	.	.	O

Inflammatory	inflammatory	JJ	O
stimuli	stimulus	NNS	O
trigger	trigger	VBP	O
a	a	DT	O
signalling	signal	VBG	O
cascade	cascade	NN	O
mediated	mediate	VBN	O
by	by	IN	O
p38	p38	NN	O
MAPK	MAPK	NNP	O
,	,	,	O
which	which	WDT	O
activates	activate	VBZ	O
transcription	transcription	NN	O
and	and	CC	O
translation	translation	NN	O
of	of	IN	O
genes	gene	NNS	O
associated	associate	VBN	O
with	with	IN	O
inflammatory	inflammatory	JJ	O
responses	response	NNS	O
such	such	JJ	O
as	as	IN	O
TNF	TNF	NNP	O
-	-	HYPH	O
Î±	Î±	NNP	O
,	,	,	O
IL-1Î²	IL-1Î²	NNP	O
and	and	CC	O
IL-6	il-6	JJ	O
,	,	,	O
and	and	CC	O
further	far	RBR	O
induces	induce	VBZ	O
the	the	DT	O
expression	expression	NN	O
of	of	IN	O
inflammatory	inflammatory	JJ	O
mediators	mediator	NNS	O
such	such	JJ	O
as	as	IN	O
COX-2	COX-2	NNP	O
,	,	,	O
iNOS	inos	NN	O
and	and	CC	O
adhesion	adhesion	NN	O
molecules	molecule	NNS	B
.	.	.	O

Considering	consider	VBG	O
this	this	DT	O
,	,	,	O
we	-PRON-	PRP	O
examined	examine	VBD	O
the	the	DT	O
impact	impact	NN	O
of	of	IN	O
6n	6n	CD	O
on	on	IN	O
the	the	DT	O
phosphorylation	phosphorylation	NN	O
of	of	IN	O
the	the	DT	O
three	three	CD	O
MAPK	MAPK	NNP	O
subtypes	subtype	NNS	O
,	,	,	O
including	include	VBG	O
p38	p38	NN	O
,	,	,	O
JNK	JNK	NNP	O
and	and	CC	O
ERK	ERK	NNP	O
.	.	.	O

As	as	IN	O
a	a	DT	O
result	result	NN	O
,	,	,	O
6n	6n	WP	O
can	can	MD	O
significantly	significantly	RB	O
lower	lower	VB	O
p38	p38	NN	O
phosphorylation	phosphorylation	NN	O
Figure	Figure	NNP	O
7	7	CD	O
,	,	,	O
though	though	IN	O
there	there	EX	O
was	be	VBD	O
no	no	DT	O
obvious	obvious	JJ	O
effect	effect	NN	O
on	on	IN	O
the	the	DT	O
phosphorylation	phosphorylation	NN	O
of	of	IN	O
JNK	JNK	NNP	O
Figure	Figure	NNP	O
7	7	CD	O
and	and	CC	O
ERK	ERK	NNP	O
Figure	Figure	NNP	O
7	7	CD	O
.	.	.	O

These	these	DT	O
results	result	NNS	O
suggested	suggest	VBD	O
that	that	IN	O
the	the	DT	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
effect	effect	NN	O
of	of	IN	O
6n	6n	CD	O
was	be	VBD	O
related	relate	VBN	O
to	to	IN	O
the	the	DT	O
inhibition	inhibition	NN	O
of	of	IN	O
p38	p38	NNP	O
phosphorylation	phosphorylation	NN	O
.	.	.	O

Compound	compound	NN	O
6n	6n	CD	O
inhibited	inhibit	VBD	O
LPS	LPS	NNP	O
-	-	HYPH	O
induced	induce	VBN	O
MAPK	MAPK	NNP	O
-	-	HYPH	O
signalling	signal	VBG	O
activation	activation	NN	O
in	in	IN	O
RAW264.7	RAW264.7	NNP	O
cells	cell	NNS	O
.	.	.	O

RAW264.7	RAW264.7	NNP	O
cells	cell	NNS	O
were	be	VBD	O
co	co	VBN	O
-	-	VBN	O
incubated	incubate	VBN	O
with	with	IN	O
6n	6n	NNP	O
5	5	CD	O
,	,	,	O
10	10	CD	O
,	,	,	O
20âÎ¼M	20âî¼m	CD	O
and	and	CC	O
LPS	LPS	NNP	O
200âng	200âng	CD	O
/	/	SYM	O
mL	ml	NN	O
for	for	IN	O
30âmin	30âmin	NNP	O
.	.	.	O

The	the	DT	O
levels	level	NNS	O
of	of	IN	O
p38	p38	NNP	O
,	,	,	O
JNK	JNK	NNP	O
,	,	,	O
ERK1/2	ERK1/2	.	O
and	and	CC	O
their	-PRON-	PRP$	O
phosphorylated	phosphorylated	JJ	O
forms	form	NNS	O
were	be	VBD	O
analysed	analyse	VBN	O
using	use	VBG	O
western	western	JJ	O
blot	blot	NN	O
.	.	.	O

The	the	DT	O
results	result	NNS	O
were	be	VBD	O
showed	show	VBN	O
as	as	IN	O
meansâÂ±âSD	meansâÂ±âSD	NNP	O
nâ=â3	nâ=â3	NNP	O
;	;	:	O
*	*	NFP	O
*	*	NFP	O
pâ<â0.01	pâ<â0.01	VBP	O
vs	vs	IN	O
compared	compare	VBN	O
with	with	IN	O
the	the	DT	O
control	control	NN	O
group	group	NN	O
;	;	:	O
#	#	$	O
pâ<â0.05	pâ<â0.05	NNP	O
,	,	,	O
#	#	$	O
#	#	$	O
pâ<â0.01	pâ<â0.01	-LRB-	O
vs	vs	FW	O
compare	compare	VB	O
with	with	IN	O
LPS	LPS	NNP	O
-	-	HYPH	O
stimulated	stimulate	VBN	O
group	group	NN	O
.	.	.	O

The	the	DT	O
down	down	IN	O
-	-	HYPH	O
regulation	regulation	NN	O
of	of	IN	O
p38	p38	NN	O
MAPK	MAPK	NNP	O
phosphorylation	phosphorylation	NN	O
by	by	IN	O
6n	6n	CD	O
may	may	MD	O
be	be	VB	O
attributed	attribute	VBN	O
to	to	IN	O
its	-PRON-	PRP$	O
interaction	interaction	NN	O
with	with	IN	O
the	the	DT	O
upstream	upstream	JJ	O
effector	effector	NN	O
.	.	.	O

Besides	besides	RB	O
,	,	,	O
owing	owe	VBG	O
to	to	IN	O
the	the	DT	O
structural	structural	JJ	O
similarity	similarity	NN	O
of	of	IN	O
the	the	DT	O
target	target	NN	O
compounds	compound	NNS	O
to	to	IN	O
talmapimod	talmapimod	NNP	O
,	,	,	O
their	-PRON-	PRP$	O
inhibition	inhibition	NN	O
against	against	IN	O
p38Î±	p38Î±	NNP	O
MAPK	MAPK	NNP	O
was	be	VBD	O
expected	expect	VBN	O
.	.	.	O

This	this	DT	O
concurrent	concurrent	JJ	O
inhibition	inhibition	NN	O
of	of	IN	O
p38Î±	p38Î±	NNP	O
MAPK	MAPK	NNP	O
and	and	CC	O
its	-PRON-	PRP$	O
upstream	upstream	JJ	O
effector	effector	NN	O
would	would	MD	O
contribute	contribute	VB	O
to	to	IN	O
a	a	DT	O
two	two	CD	O
-	-	HYPH	O
spot	spot	NN	O
ablation	ablation	NN	O
of	of	IN	O
p38Î±	p38Î±	NNP	O
MAPK	MAPK	NNP	O
-	-	HYPH	O
related	relate	VBN	O
signalling	signalling	NN	O
pathway	pathway	NN	O
,	,	,	O
which	which	WDT	O
might	may	MD	O
be	be	VB	O
beneficial	beneficial	JJ	O
to	to	IN	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
treatment	treatment	NN	O
.	.	.	O

Thereby	thereby	RB	O
,	,	,	O
6f	6f	NNS	O
,	,	,	O
6j	6j	NNS	O
,	,	,	O
6n	6n	CD	O
and	and	CC	O
8	8	CD	O
,	,	,	O
with	with	IN	O
strong	strong	JJ	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
activity	activity	NN	O
,	,	,	O
were	be	VBD	O
further	further	RB	O
evaluated	evaluate	VBN	O
against	against	IN	O
p38Î±	p38Î±	NNP	O
MAPK	MAPK	NNP	O
with	with	IN	O
SB203580	sb203580	NN	O
,	,	,	O
a	a	DT	O
selective	selective	JJ	O
p38Î±	p38Î±	NNP	O
MAPK	MAPK	NNP	O
inhibitor	inhibitor	NN	O
,	,	,	O
as	as	IN	O
the	the	DT	O
reference	reference	NN	O
.	.	.	O

Besides	besides	RB	O
,	,	,	O
we	-PRON-	PRP	O
also	also	RB	O
evaluated	evaluate	VBD	O
them	-PRON-	PRP	O
against	against	IN	O
COX-2	COX-2	NNP	O
,	,	,	O
a	a	DT	O
well	well	RB	O
-	-	HYPH	O
established	establish	VBN	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
target	target	NN	O
,	,	,	O
given	give	VBN	O
the	the	DT	O
correlation	correlation	NN	O
of	of	IN	O
COX-2	COX-2	NNP	O
with	with	IN	O
MAPK	MAPK	NNP	O
signalling	signalling	NN	O
.	.	.	O

The	the	DT	O
results	result	NNS	O
demonstrated	demonstrate	VBD	O
that	that	IN	O
6n	6n	CD	O
exhibited	exhibit	VBD	O
attractive	attractive	JJ	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
against	against	IN	O
p38Î±	p38Î±	NNP	O
MAPK	MAPK	NNP	O
with	with	IN	O
IC50	IC50	NNP	O
value	value	NN	O
of	of	IN	O
1.95âÂµM	1.95âÂµM	NNP	O
,	,	,	O
along	along	IN	O
with	with	IN	O
potent	potent	JJ	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
against	against	IN	O
COX-2	COX-2	NNP	O
with	with	IN	O
IC50	IC50	NNP	O
value	value	NN	O
of	of	IN	O
0.036âÂµM	0.036ââµm	NN	O
,	,	,	O
which	which	WDT	O
was	be	VBD	O
comparable	comparable	JJ	O
to	to	IN	O
that	that	DT	O
of	of	IN	O
Celecoxib	Celecoxib	NNP	O
.	.	.	O

Besides	besides	RB	O
,	,	,	O
it	-PRON-	PRP	O
inhibited	inhibit	VBD	O
COX-2	cox-2	JJ	O
with	with	IN	O
a	a	DT	O
favourable	favourable	JJ	O
selectivity	selectivity	NN	O
,	,	,	O
which	which	WDT	O
was	be	VBD	O
beneficial	beneficial	JJ	O
to	to	IN	O
lowering	lower	VBG	O
gastrointestinal	gastrointestinal	JJ	O
intolerance	intolerance	NN	O
.	.	.	O

The	the	DT	O
concomitant	concomitant	JJ	O
inhibition	inhibition	NN	O
of	of	IN	O
p38Î±	p38Î±	NNP	O
MAPK	MAPK	NNP	O
,	,	,	O
its	-PRON-	PRP$	O
upstream	upstream	NN	O
effector	effector	NN	O
,	,	,	O
as	as	RB	O
well	well	RB	O
as	as	IN	O
COX-2	COX-2	NNP	O
may	may	MD	O
account	account	VB	O
for	for	IN	O
the	the	DT	O
most	most	RBS	O
favourable	favourable	JJ	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
activity	activity	NN	O
of	of	IN	O
6n	6n	CD	O
.	.	.	O

In	in	IN	O
addition	addition	NN	O
,	,	,	O
compound	compound	NN	O
6j	6j	NNS	O
was	be	VBD	O
identified	identify	VBN	O
as	as	IN	O
a	a	DT	O
potent	potent	JJ	O
inhibitor	inhibitor	NN	O
against	against	IN	O
COX-2	COX-2	NNP	O
with	with	IN	O
IC50	IC50	NNP	O
value	value	NN	O
of	of	IN	O
0.022âÂµM	0.022ââµm	NN	O
,	,	,	O
while	while	IN	O
compound	compound	NNP	O
8	8	CD	O
was	be	VBD	O
characterised	characterise	VBN	O
as	as	IN	O
a	a	DT	O
potent	potent	JJ	O
inhibitor	inhibitor	NN	O
against	against	IN	O
p38Î±	p38Î±	NNP	O
MAPK	MAPK	NNP	O
with	with	IN	O
IC50	IC50	NNP	O
value	value	NN	O
of	of	IN	O
1.05âÂµM	1.05âÂµM	NNP	O
.	.	.	O

P38Î±	P38Î±	NNP	O
MAPK	MAPK	NNP	O
,	,	,	O
COX-1	cox-1	NN	O
and	and	CC	O
COX-2	cox-2	JJ	O
inhibition	inhibition	NN	O
activity	activity	NN	O
inÂ	inÂ	NNP	O
vitro	vitro	FW	O
.	.	.	O

ND	ND	NNP	O
:	:	:	O
not	not	RB	O
determined	determined	JJ	O
.	.	.	O

IC50	ic50	NN	O
:	:	:	O
Represents	represent	VBZ	O
the	the	DT	O
concentration	concentration	NN	O
of	of	IN	O
the	the	DT	O
test	test	NN	O
compound	compound	NN	O
that	that	WDT	O
is	be	VBZ	O
required	require	VBN	O
for	for	IN	O
50	50	CD	O
%	%	NN	O
inhibition	inhibition	NN	O
inÂ	inÂ	NNP	O
vitro	vitro	FW	O
.	.	.	O

The	the	DT	O
molecular	molecular	JJ	O
docking	docking	NN	O
analysis	analysis	NN	O
of	of	IN	O
6f	6f	NNPS	O
,	,	,	O
6j	6j	NNS	O
,	,	,	O
6n	6n	CD	O
and	and	CC	O
8	8	CD	O
was	be	VBD	O
carried	carry	VBN	O
out	out	RP	O
to	to	TO	O
elucidate	elucidate	VB	O
their	-PRON-	PRP$	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
activity	activity	NN	O
inÂ	inÂ	NNP	O
vitro	vitro	FW	O
.	.	.	O

As	as	IN	O
showed	show	VBN	O
in	in	IN	O
Table	table	NN	O
3	3	CD	O
,	,	,	O
8	8	CD	O
exhibited	exhibit	VBD	O
the	the	DT	O
lowest	low	JJS	O
binding	binding	JJ	O
energy	energy	NN	O
value	value	NN	O
â8.98âkcal	â8.98âkcal	NNP	O
/	/	SYM	O
mol	mol	NN	O
when	when	WRB	O
they	-PRON-	PRP	O
docked	dock	VBD	O
with	with	IN	O
p38Î±	p38Î±	NNP	O
MAPK	MAPK	NNP	O
,	,	,	O
and	and	CC	O
6f	6f	NNS	O
bound	bind	VBN	O
to	to	IN	O
COX-2	cox-2	JJ	O
active	active	JJ	O
site	site	NN	O
with	with	IN	O
best	good	JJS	O
binding	binding	JJ	O
energy	energy	NN	O
value	value	NN	O
of	of	IN	O
â7.82âkcal	â7.82âkcal	NNP	O
/	/	SYM	O
mol	mol	NN	O
.	.	.	O

This	this	DT	O
was	be	VBD	O
consistent	consistent	JJ	O
with	with	IN	O
the	the	DT	O
above	above	RB	O
-	-	HYPH	O
mentioned	mention	VBN	O
inÂ	inÂ	NNP	O
vitro	vitro	FW	O
enzymatic	enzymatic	JJ	O
experiment	experiment	NN	O
results	result	NNS	O
.	.	.	O

Docking	docking	NN	O
results	result	NNS	O
of	of	IN	O
6f	6f	NNS	O
,	,	,	O
6j	6j	NNS	O
,	,	,	O
6n	6n	CD	O
and	and	CC	O
8The	8The	``	O
prominent	prominent	JJ	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
against	against	IN	O
p38Î±	p38Î±	NNP	O
MAPK	MAPK	NNP	O
and	and	CC	O
COX-2	COX-2	NNP	O
contributed	contribute	VBD	O
to	to	IN	O
the	the	DT	O
most	most	RBS	O
potent	potent	JJ	O
inÂ	inÂ	NNP	O
vivo	vivo	NNP	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
activity	activity	NN	O
of	of	IN	O
6n	6n	CD	O
.	.	.	O

It	-PRON-	PRP	O
bound	bind	VBD	O
to	to	IN	O
the	the	DT	O
p38Î±	p38Î±	NNP	O
MAPK	MAPK	NNP	O
active	active	JJ	O
site	site	NN	O
in	in	IN	O
a	a	DT	O
similar	similar	JJ	O
manner	manner	NN	O
to	to	IN	O
the	the	DT	O
co	co	JJ	O
-	-	JJ	O
crystallized	crystallized	JJ	O
ligand	ligand	NN	O
Figure	Figure	NNP	O
8)	8)	CD	O
,	,	,	O
with	with	IN	O
the	the	DT	O
amide	amide	JJ	O
carbonyl	carbonyl	NN	O
engaged	engage	VBD	O
in	in	IN	O
H	h	NN	O
-	-	HYPH	O
bond	bond	NN	O
contacts	contact	NNS	O
with	with	IN	O
residues	residue	NNS	O
Met	Met	NNP	O
109	109	CD	O
and	and	CC	O
Gly	Gly	NNP	O
110	110	CD	O
in	in	IN	O
the	the	DT	O
hinge	hinge	NN	O
region	region	NN	O
,	,	,	O
and	and	CC	O
2-methoxybenzyl	2-methoxybenzyl	CD	O
projected	project	VBD	O
into	into	IN	O
the	the	DT	O
hydrophobic	hydrophobic	JJ	O
pocket	pocket	NN	O
formed	form	VBN	O
by	by	IN	O
Thr	Thr	NNP	O
106	106	CD	O
,	,	,	O
Val	Val	NNP	O
105	105	CD	O
,	,	,	O
Leu	Leu	NNP	O
104	104	NNP	O
and	and	CC	O
Lys	Lys	NNP	O
53	53	CD	O
Figure	figure	NN	O
8)	8)	CD	O
.	.	.	O

Moreover	moreover	RB	O
,	,	,	O
the	the	DT	O
molecular	molecular	JJ	O
docking	docking	NN	O
results	result	NNS	O
also	also	RB	O
accounted	account	VBD	O
for	for	IN	O
the	the	DT	O
potency	potency	NN	O
of	of	IN	O
6n	6n	NNP	O
against	against	IN	O
COX-2	COX-2	NNP	O
and	and	CC	O
its	-PRON-	PRP$	O
COX-2	cox-2	JJ	O
selectivity	selectivity	NN	O
.	.	.	O

In	in	IN	O
compared	compare	VBN	O
with	with	IN	O
COX-1	COX-1	NNP	O
,	,	,	O
the	the	DT	O
active	active	JJ	O
site	site	NN	O
of	of	IN	O
COX-2	COX-2	NNP	O
featured	feature	VBD	O
an	an	DT	O
additional	additional	JJ	O
side	side	NN	O
pocket	pocket	NN	O
surrounded	surround	VBN	O
by	by	IN	O
Val	Val	NNP	O
523	523	CD	O
,	,	,	O
Leu	Leu	NNP	O
352	352	CD	O
and	and	CC	O
Ser	Ser	NNP	O
353	353	CD	B
,	,	,	B
.	.	.	O

The	the	DT	O
2-methoxybenzyl	2-methoxybenzyl	CD	O
moiety	moiety	NN	O
of	of	IN	O
6n	6n	NNP	O
was	be	VBD	O
embedded	embed	VBN	O
in	in	IN	O
this	this	DT	O
pocket	pocket	NN	O
,	,	,	O
with	with	IN	O
the	the	DT	O
methoxyl	methoxyl	NNP	O
group	group	NN	O
forming	form	VBG	O
two	two	CD	O
critical	critical	JJ	O
H	h	NN	O
-	-	:	O
bonds	bond	NNS	O
with	with	IN	O
Arg	Arg	NNP	O
513	513	CD	O
and	and	CC	O
His	-PRON-	PRP$	O
90	90	CD	O
,	,	,	O
and	and	CC	O
the	the	DT	O
piperazine	piperazine	NN	O
nitrogen	nitrogen	NN	O
tethered	tether	VBD	O
to	to	IN	O
the	the	DT	O
2-methoxybenzyl	2-methoxybenzyl	CD	O
moiety	moiety	NN	O
formed	form	VBD	O
a	a	DT	O
H	h	NN	O
-	-	HYPH	O
bond	bond	NN	O
with	with	IN	O
Lue	Lue	NNP	O
352	352	CD	O
at	at	IN	O
the	the	DT	O
mouth	mouth	NN	O
of	of	IN	O
the	the	DT	O
pocket	pocket	NN	O
.	.	.	O

Furthermore	furthermore	RB	O
,	,	,	O
the	the	DT	O
acetyl	acetyl	NN	O
on	on	IN	O
benzene	benzene	NN	O
ring	ring	NN	O
was	be	VBD	O
located	locate	VBN	O
at	at	IN	O
the	the	DT	O
other	other	JJ	O
end	end	NN	O
of	of	IN	O
the	the	DT	O
active	active	JJ	O
site	site	NN	O
and	and	CC	O
was	be	VBD	O
involved	involve	VBN	O
with	with	IN	O
H	h	NN	O
-	-	HYPH	O
bond	bond	NN	O
contact	contact	NN	O
with	with	IN	O
Arg	arg	NN	O
120	120	CD	O
Figure	figure	NN	O
8)	8)	CD	O
.	.	.	O

Interestingly	interestingly	RB	O
,	,	,	O
due	due	IN	O
to	to	IN	O
the	the	DT	O
lack	lack	NN	O
of	of	IN	O
the	the	DT	O
side	side	NN	O
pocket	pocket	NN	O
,	,	,	O
the	the	DT	O
binding	bind	VBG	O
poses	pose	NNS	O
of	of	IN	O
6n	6n	CD	O
in	in	IN	O
the	the	DT	O
COX-1	cox-1	JJ	O
active	active	JJ	O
site	site	NN	O
was	be	VBD	O
forced	force	VBN	O
to	to	TO	O
rotate	rotate	VB	O
and	and	CC	O
the	the	DT	O
above	above	IN	O
binding	bind	VBG	O
interactions	interaction	NNS	O
was	be	VBD	O
also	also	RB	O
absent	absent	JJ	O
Figure	figure	NN	O
8)	8)	CD	O
.	.	.	O

Overlay	overlay	NN	O
of	of	IN	O
docking	docking	NN	O
poses	pose	NNS	O
of	of	IN	O
6n	6n	CD	O
and	and	CC	O
the	the	DT	O
co	co	JJ	O
-	-	JJ	O
crystallised	crystallised	JJ	O
ligand	ligand	NN	O
in	in	IN	O
the	the	DT	O
binding	bind	VBG	O
site	site	NN	O
of	of	IN	O
p38Î±	p38Î±	NNP	O
MAPK	MAPK	NNP	O
.	.	.	O

Docking	docking	NN	O
and	and	CC	O
binding	bind	VBG	O
pattern	pattern	NN	O
of	of	IN	O
6n	6n	CD	O
into	into	IN	O
p38Î±	p38Î±	NNP	O
MAPK	MAPK	NNP	O
active	active	JJ	O
site	site	NN	O
.	.	.	O

Docking	docking	NN	O
and	and	CC	O
binding	bind	VBG	O
pattern	pattern	NN	O
of	of	IN	O
6n	6n	CD	O
into	into	IN	O
COX-2	cox-2	JJ	O
active	active	JJ	O
site	site	NN	O
.	.	.	O

Docking	docking	NN	O
and	and	CC	O
binding	bind	VBG	O
pattern	pattern	NN	O
of	of	IN	O
6n	6n	CD	O
into	into	IN	O
COX-1	cox-1	JJ	O
active	active	JJ	O
site	site	NN	O
.	.	.	O

Dashed	dash	VBN	O
lines	line	NNS	O
represent	represent	VBP	O
hydrogen	hydrogen	NN	O
bonds	bond	NNS	O
.	.	.	O

In	in	IN	O
comparison	comparison	NN	O
to	to	TO	O
compound	compound	VB	O
6n	6n	CD	O
,	,	,	O
6j	6j	NNS	O
bound	bind	VBD	O
more	more	RBR	O
strongly	strongly	RB	O
to	to	IN	O
the	the	DT	O
pivotal	pivotal	JJ	O
residue	residue	NN	O
,	,	,	O
that	that	RB	O
is	is	RB	O
,	,	,	O
Leu	Leu	NNP	O
352	352	CD	O
Figure	Figure	NNP	O
9	9	CD	O
.	.	.	O

This	this	DT	O
may	may	MD	O
be	be	VB	O
the	the	DT	O
reason	reason	NN	O
why	why	WRB	O
6j	6j	PRP	O
had	have	VBD	O
lower	low	JJR	O
binging	binge	VBG	O
energy	energy	NN	O
value	value	NN	O
and	and	CC	O
better	well	JJR	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
against	against	IN	O
COX-2	COX-2	NNP	O
.	.	.	O

Loss	loss	NN	O
of	of	IN	O
two	two	CD	O
critical	critical	JJ	O
H	h	NN	O
-	-	:	O
bonds	bond	NNS	O
with	with	IN	O
Leu	Leu	NNP	O
352	352	CD	O
and	and	CC	O
Arg	Arg	NNP	O
120	120	CD	O
,	,	,	O
the	the	DT	O
binding	bind	VBG	O
poses	pose	NNS	O
of	of	IN	O
6f	6f	NNS	O
in	in	IN	O
COX-2	cox-2	JJ	O
active	active	JJ	O
site	site	NN	O
was	be	VBD	O
reversed	reverse	VBN	O
Figure	Figure	NNP	O
9	9	CD	O
,	,	,	O
and	and	CC	O
it	-PRON-	PRP	O
presented	present	VBD	O
the	the	DT	O
lowest	low	JJS	O
binging	binging	NN	O
energy	energy	NN	O
value	value	NN	O
â7.55âkcal	â7.55âkcal	NNP	O
/	/	SYM	O
mol	mol	NN	O
to	to	IN	O
other	other	JJ	O
analogues	analogue	NNS	O
.	.	.	O

Correspondingly	correspondingly	RB	O
,	,	,	O
the	the	DT	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
of	of	IN	O
6f	6f	NNS	O
against	against	IN	O
COX-2	COX-2	NNP	O
was	be	VBD	O
declining	decline	VBG	O
substantially	substantially	RB	O
.	.	.	O

The	the	DT	O
result	result	NN	O
of	of	IN	O
hydrogen	hydrogen	NN	O
boding	boding	NN	O
analyses	analysis	NNS	O
may	may	MD	O
justify	justify	VB	O
that	that	IN	O
the	the	DT	O
H	h	NN	O
-	-	HYPH	O
bonds	bond	NNS	O
with	with	IN	O
Leu	Leu	NNP	O
352	352	CD	O
and	and	CC	O
Arg	Arg	NNP	O
120	120	CD	O
were	be	VBD	O
decisive	decisive	JJ	O
factor	factor	NN	O
for	for	IN	O
presence	presence	NN	O
of	of	IN	O
COX-2	cox-2	JJ	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
in	in	IN	O
this	this	DT	O
series	series	NN	O
of	of	IN	O
analogues	analogue	NNS	O
.	.	.	O

Docking	docking	NN	O
and	and	CC	O
binding	bind	VBG	O
pattern	pattern	NN	O
of	of	IN	O
6j	6j	CD	O
into	into	IN	O
COX-2	cox-2	JJ	O
active	active	JJ	O
site	site	NN	O
.	.	.	O

Docking	docking	NN	O
and	and	CC	O
binding	bind	VBG	O
pattern	pattern	NN	O
of	of	IN	O
6f	6f	NNS	O
into	into	IN	O
COX-2	cox-2	JJ	O
active	active	JJ	O
site	site	NN	O
.	.	.	O

Dashed	dash	VBN	O
lines	line	NNS	O
represent	represent	VBP	O
hydrogen	hydrogen	NN	O
bonds	bond	NNS	O
.	.	.	O

In	in	IN	O
conclusion	conclusion	NN	O
,	,	,	O
we	-PRON-	PRP	O
have	have	VBP	O
designed	design	VBN	O
and	and	CC	O
synthesised	synthesise	VBN	O
a	a	DT	O
series	series	NN	O
of	of	IN	O
talmapimod	talmapimod	NNP	O
analogues	analogue	NNS	O
as	as	IN	O
the	the	DT	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
agents	agent	NNS	O
based	base	VBN	O
on	on	IN	O
an	an	DT	O
unexpected	unexpected	JJ	O
product	product	NN	O
6a	6a	CD	O
obtained	obtain	VBN	O
from	from	IN	O
an	an	DT	O
internal	internal	JJ	O
programme	programme	NN	O
to	to	TO	O
prepare	prepare	VB	O
butylphthalide	butylphthalide	JJ	O
derivatives	derivative	NNS	O
.	.	.	O

Among	among	IN	O
these	these	DT	O
compounds	compound	NNS	O
,	,	,	O
6n	6n	CD	O
exerted	exert	VBD	O
the	the	DT	O
best	good	JJS	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
activity	activity	NN	O
inÂ	inÂ	NNP	O
vivo	vivo	NNP	O
.	.	.	O

As	as	IN	O
illustrated	illustrate	VBN	O
by	by	IN	O
the	the	DT	O
mechanism	mechanism	NN	O
study	study	NN	O
,	,	,	O
6n	6n	NN	O
-	-	HYPH	O
treatment	treatment	NN	O
culminated	culminate	VBN	O
in	in	IN	O
a	a	DT	O
dose	dose	RB	O
-	-	HYPH	O
dependent	dependent	JJ	O
decrease	decrease	NN	O
in	in	IN	O
the	the	DT	O
LPS	LPS	NNP	O
-	-	HYPH	O
induced	induce	VBN	O
expressions	expression	NNS	O
of	of	IN	O
iNOS	inos	NN	O
and	and	CC	O
COX-2	COX-2	NNP	O
.	.	.	O

Besides	besides	RB	O
,	,	,	O
6n	6n	CD	O
-	-	HYPH	O
treatment	treatment	NN	O
led	lead	VBD	O
to	to	IN	O
the	the	DT	O
dose	dose	RB	O
-	-	HYPH	O
dependent	dependent	JJ	O
down	down	NN	O
-	-	HYPH	O
regulations	regulation	NNS	O
of	of	IN	O
NF	NF	NNP	O
-	-	HYPH	O
ÎºB	ÎºB	NNP	O
signalling	signal	VBG	O
pathway	pathway	NN	O
and	and	CC	O
the	the	DT	O
p38	p38	NNP	O
MAPK	MAPK	NNP	O
phosphorylation	phosphorylation	NN	O
,	,	,	O
both	both	DT	O
of	of	IN	O
which	which	WDT	O
may	may	MD	O
contribute	contribute	VB	O
to	to	IN	O
the	the	DT	O
decrease	decrease	NN	O
in	in	IN	O
LPS	LPS	NNP	O
-	-	HYPH	O
induced	induce	VBN	O
expressions	expression	NNS	O
of	of	IN	O
iNOS	inos	NN	O
and	and	CC	O
COX-2	COX-2	NNP	O
.	.	.	O

The	the	DT	O
down	down	NN	O
-	-	HYPH	O
regulation	regulation	NN	O
of	of	IN	O
p38	p38	NNP	O
MAPK	MAPK	NNP	O
phosphorylation	phosphorylation	NN	O
indicated	indicate	VBD	O
the	the	DT	O
inhibition	inhibition	NN	O
of	of	IN	O
the	the	DT	O
upstream	upstream	JJ	O
effector	effector	NN	O
of	of	IN	O
p38	p38	NNP	O
MAPK	MAPK	NNP	O
.	.	.	O

Further	further	RB	O
inÂ	inÂ	NNP	O
vitro	vitro	FW	O
enzymatic	enzymatic	JJ	O
experiment	experiment	NN	O
identified	identify	VBD	O
6n	6n	NNP	O
as	as	IN	O
a	a	DT	O
potent	potent	JJ	O
inhibitor	inhibitor	NN	O
against	against	IN	O
both	both	CC	O
p38Î±	p38Î±	NNP	O
MAPK	MAPK	NNP	O
and	and	CC	O
COX-2	COX-2	NNP	O
.	.	.	O

To	to	IN	O
our	-PRON-	PRP$	O
knowledge	knowledge	NN	O
,	,	,	O
this	this	DT	O
has	have	VBZ	O
been	be	VBN	O
the	the	DT	O
first	first	JJ	O
compound	compound	NN	O
reported	report	VBD	O
to	to	TO	O
exert	exert	VB	O
p38Î±	p38Î±	NNP	O
MAPK	MAPK	NNP	O
and	and	CC	O
COX-2	cox-2	JJ	O
inhibitory	inhibitory	NN	O
activities	activity	NNS	O
.	.	.	O

Importantly	importantly	RB	O
,	,	,	O
the	the	DT	O
concomitant	concomitant	JJ	O
inhibition	inhibition	NN	O
of	of	IN	O
p38Î±	p38Î±	NNP	O
MAPK	MAPK	NNP	O
,	,	,	O
its	-PRON-	PRP$	O
upstream	upstream	NN	O
effector	effector	NN	O
,	,	,	O
and	and	CC	O
COX-2	COX-2	NNP	O
,	,	,	O
along	along	IN	O
with	with	IN	O
its	-PRON-	PRP$	O
confirmed	confirm	VBN	O
capability	capability	NN	O
to	to	IN	O
down	down	IN	O
-	-	HYPH	O
regulate	regulate	NN	O
NF	NF	NNP	O
-	-	HYPH	O
ÎºB	ÎºB	NNP	O
and	and	CC	O
MAPK	MAPK	NNP	O
-	-	HYPH	O
signalling	signal	VBG	O
pathways	pathway	NNS	O
make	make	VBP	O
6n	6n	CD	O
a	a	DT	O
promising	promising	JJ	O
polypharmacological	polypharmacological	JJ	O
anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
agent	agent	NN	O
.	.	.	O

The	the	DT	O
further	further	JJ	O
investigation	investigation	NN	O
of	of	IN	O
6n	6n	NNP	O
has	have	VBZ	O
been	be	VBN	O
currently	currently	RB	O
underway	underway	JJ	O
.	.	.	O

Anti	anti	JJ	O
-	-	JJ	O
inflammatory	inflammatory	JJ	O
molecular	molecular	JJ	O
mechanism	mechanism	NN	O
of	of	IN	O
6n	6n	CD	O
.	.	.	O

